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ABSTRACT
An estimated 100 million Americans suffer from some form of chronic pain. Chronic
opioid therapy (COT) use in non-malignant chronic pain patients (NMCPP) has markedly
increased over the past two decades due to growing consensus that COT is suitable for the
treatment of moderate-to-severe non-malignant chronic pain. Yet, COT for NMCPP has been
widely associated with multiple aberrant drug-related behaviors (ADRB) such as misuse, abuse,
diversion, addiction, and pseudoaddiction. One reason for the relative high incidence of ADRB
among NMCPP on COT may be genetics-induced medication response variability, which, can
result in pharmacotherapy failure and/or toxicity
The present study evaluated the relationships between opioid metabolizer status (OMS)
(caused by inter-personal genetic variability in opioid metabolism) and ADRB such as illicit
substance abuse and prescription opioid misuse. Pharmacogenetic testing (PGT) was used to
categorize patient OMS, whereas urine drug testing (UDT) identified relevant ADRB. To test the
study’s hypothesis, retrospective categorical data from an assembled cohort of NMCPP on COT
was retrieved from a Pain Management Clinic’s electronic medical records system (EMR). PGT
and UDT results were cross-tabulated and analyzed with the Pearson Chi-square test for difference
in proportions. Confounding and effect modification were dealt with by the inclusion of suspect
variables Race/Ethnicity and Sex in a logistic regression model.
The results of the study showed that there was no statistically significant association
between opioid metabolizer status and aberrant drug-related behaviors nor between the two suspect
confounding variables and aberrant drug-related behaviors.
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CHAPTER 1

INTRODUCTION
1.1 Background
1.1.1 Chronic Pain
An estimated 100 million Americans suffer from some form of chronic pain with a
prevalence among adults likely to be as high as 40% (Institute of Medicine, 2011; Webster, L.,
2010; Cone et al., 2008). Chronic pain, defined as pain which lasts more than 3-6 months or lasting
beyond the normal healing process (Warner, 2012; Institute of Medicine, 2011), is considered the
leading cause of disability, the primary reason for physician visits, and a key factor in reduced
quality of life and productivity (Webster, L., 2010; Cone et al., 2008). The costs associated with
chronic pain, including health care and opportunity costs, amount to an estimated $560-635 billion
annual expenditure in the United States (National Academies of Sciences, Engineering, and
Medicine, 2016; Institute of Medicine, 2011).
1.1.2 Treatment for Chronic Pain
Since complete remission of chronic pain is rarely achieved, the focus of treatment
therapies consists of attempts at improving quality of life through a multi-modal approach:
psychotherapy, physical therapy, alternative medicine, interventional procedures, and
pharmacotherapy (Webster, L., 2010; Chou et al., 2009). Chronic opioid pharmacotherapy in nonmalignant chronic pain patients (NMCPP) has markedly increased over the past two decades due
to growing consensus among medical providers that chronic opioid therapy (COT) is suitable for
the treatment of moderate-to-severe chronic pain (Alford, 2009; Chou et al., 2009). Commonly
1

prescribed drugs in COT include codeine, morphine, hydrocodone, hydromorphone, Oxycodone,
Oxymorphone, Fentanyl and Tramadol (Trescot, Datta, Lee, & Hansen, 2008).
1.1.3 Aberrant Drug-Related Behaviors (ADRB)
COT for NMCPP has been widely associated with multiple aberrant drug-related behaviors
(ADRB) such as misuse, abuse, diversion, addiction, and pseudoaddiction (Smith et al., 2013;
Webster, L., 2010). Misuse is the use of prescription or over-the-counter medications in a manner
that contradicts medical advice. Abuse entails an intentional, non-therapeutic use of a drug (both
licit and illicit) for the purpose of achieving its psychotropic effects. Diversion is the removal of a
drug from legal distribution channels. Addiction refers to the behavioral, cognitive, and
physiological phenomena that an individual may develop after exposure to a substance, which may
include a strong desire to take the drug, difficulties in controlling its use, persistent use despite
harmful consequences, intractable and distracting thoughts about the drug, and placing a higher
priority on drug use than on any other activities (Smith et al., 2013).
1.1.4 Adherence Monitoring and Genetic Testing
Responsible prescribing of COT requires that providers commit to the use of available
clinical tools and to the application of evidence-based principles to ensure the safety of patients by
substantially reducing ADRB risk. Ideally, these clinical tools allow providers to objectively
monitor regimen adherence, categorize patients into abuse risk strata, and identify patterns of abuse
(Owen, Burton, Schade, & Passik, 2012; Peppin et al., 2012; Chou et al., 2009; Christo et al., 2011;
Manchikanti, Boswell, & Singh, 2004;). One of these tools is urine drug testing (UDT), which
provides information regarding the presence or absence of prescribed medication, illicits, and
adulterants in biological urine specimens. When compared to surveys, clinical history, prescription
2

drug monitoring program (PDMP) reports and pill counts, UDT is one of the most objective tools
for adherence monitoring/risk assessment in pain management as it is biometrically based (Lee &
Zhang, 2013; Christo et al., 2011). UDT includes both screening and confirmatory components.
The initial qualitative or semi-quantitative screening stage (presumptive) is achieved through
immunoassay testing. Yet, due to significant specificity and sensitivity limitations, there is a
second quantitative confirmatory stage (definitive) that makes use of a more advanced analytical
technique: single or tandem mass spectrometry coupled to liquid or gas chromatography (LCMS/MS, GC-MS) (Lee & Zhang, 2013; Manchikanti, Malla, Wargo, & Fellows, 2011).
Pharmacogenetic testing (PGT), another pain management tool gives providers
personalized patient genetic information like predicted metabolizer status, which enables tailored
drug therapy. Most opioid drugs used in pain management are metabolized by polymorphic
CYP450 enzymes CYP2D6, CYP3A4 and/or uridine diphosphate glucuronosyltransferase 2B7
(UGT2B7) (Jannetto & Bratanow, 2009). Drug metabolizer status from genetic polymorphisms in
the CYP2D6 gene are categorized into four groups: ultra-rapid metabolizers (UM), presenting with
multiple copies of CYP2D6; extensive metabolizers (EM) with a single wild-type copy of
CYP2D6; intermediate metabolizers (IM), exhibiting decreased enzymatic activity; and poor
metabolizers (PM), with no detectable enzyme activity (Trescot & Faynboym, 2014; Jannetto &
Bratanow, 2009).
1.1.5 Opioid Metabolism and Drug Efficacy: Genetic Testing as a Risk Assessment
Biomarker
The relatively high incidence of ADRB among NMCPP on COT may be partly the result
of pharmacotherapy failure and/or toxicity from genetic polymorphisms in the CYP2D6 enzyme,
which produce a variant or “mutant” metabolizer status for its opioid substrates (i.e. codeine,
3

hydrocodone, oxycodone, tramadol) (Trescot et al., 2008). NMCPP with genetic polymorphisms
could be misusing their prescription medication or supplementing their therapy with illicit
substances to mitigate pain when dealing with ineffective opioid drugs. At present, the risk for
opioid misuse and aberrant behaviors is largely evaluated with two validated instruments: the
Screener and Opioid Assessment for Patients with Pain- Revised (SOAPP-R) questionnaire for
COT onset, and the Current Opioid Misuse Measure (COMM) for patients already on COT
(Inflexxion, 2015). However, instruments that rely on a patient’s individual responses have a risk
of erroneously miss-categorizing these same individuals. (Moore, Jones, Browder, Daffron, &
Passik, 2009). Genetic testing, as an alternative to these instruments, could serve as a
supplementary risk assessment tool for opioid misuse and ADRB. Consequently, the aim of this
study was to uncover statistically significant associations between variant opioid metabolism
(OMS) and ADRB (i.e. misuse and abuse of licit/illicit substances). Moreover, genetic testing
could be substantially more objective than the SOAPP-R and COMM instruments since a genetic
biomarker would not be as prone to misrepresentation by determined individuals. The current
review of the literature did not conclusively establish an association between variant opioid
metabolism and ADRB (although it did establish relationships between opioid metabolism and
therapeutic failure/drug toxicity). Therefore, the findings of the present study could significantly
contribute to filling in the gaps in the body of knowledge for contributors to COT risk among
NMCPP and increasing the likelihood that we are able to mitigate that risk.
1.2 Conceptual Framework
There are three conceptual elements whose relationships were evaluated in this study:
1. Opioid metabolism – Polymorphic CYP2D6 genotype determines the metabolizer status of
an individual and how quickly (UM) or slowly (PM) an opioid prodrug (i.e. hydrocodone) is
4

biotransformed into its more potent (higher µ-opioid receptor affinity) bioactive metabolite (i.e.
hydromorphone) during Phase I of opioid metabolism.
2. Therapeutic failure and toxicity – At standard dosage, a poor opioid metabolizer could
either suffer therapy failure from low plasma concentrations of bioactive metabolite, and/or
toxicity from the buildup of high concentrations of a bioactive prodrug. The opposite could also
be true in ultra-rapid metabolizers; these patients can experience toxicity from rapid plasma
buildup of the bioactive metabolite, or therapeutic failure if most of the pain reduction stems from
the action of the parent drug.
3. Aberrant drug-related behaviors – NMCPP who are prescribed long-term opioid therapy
have a higher risk of misusing these drugs, becoming addicted to them, or abusing illicit
substances. Yet, these behaviors could have theoretically originated from efforts to supplement
COT when the drugs did not provide adequate pain relief (as would have ensued with therapy
failure in PM patients), or attempts to reduce adverse drug reactions (ADR) (as would have taken
place with toxicity in UM patients).
The scientific literature already recognizes the link between genetic makeup (opioid
metabolizer status) and drug efficacy (therapy failure/toxicity). Yet, there is no clear connection
between genetics, specifically OMS, and ADRB incidence. Therefore, I proposed that significant
relationships do exist between the conceptual elements presented above. Figure 1 graphically
depicts these relationships.

5

Figure 1. Relationships between opioid metabolism, pain relief/adverse drug reactions (ADR), and
ADRB. The figure reveals a potential relationship between opioid metabolism and ADRB.

1.3 Purpose of the Study
The purpose of this study was to assess the relationship between opioid metabolism as
determined by phenotypic CYP2D6 expression (OMS) and aberrant drug-related behaviors
(ADRB) among non-malignant chronic pain patients (NMCPP). Significant findings could further
advance the creation of better ADRB prediction algorithms for at-risk patients on a chronic opioid
regimen.

6

1.4 Definition of Terms
The following is a description of both the conceptual and operational definitions of the
variables in the study. They are presented in alphabetical order:
1. Aberrant Drug-Related Behaviors (ADRB)
a. Conceptual definition – Patient misuse, abuse, overuse and diversion of licit and illicit
drugs, as evidenced in: urine toxicological confirmatory testing (LC-MS/MS) by a finding of a
positive illicit substance (i.e. metabolites of marijuana, cocaine and heroin), positive nonprescribed medication (i.e. hydrocodone/hydromorphone), negative expected prescribed
medication, and/or positive adulteration/validity testing (i.e. pH, creatinine, oxidants); inter and
intra-state prescription drug monitoring program databases (PDMP), which uncover evidence of
doctor shopping; professional psychological evaluation; self-admission, and evidence of dose
escalation, amongst other criteria (Substance Abuse and Mental Health Services Administration,
2017; Peppin et al., 2012; Christo et al., 2011; Pergolizzi et al., 2010; Chou, Fanciullo, Fine,
Miaskowski et al., 2009; Webster, L. R. & Webster, 2005).
b. Operational definition – In this study, ADRB was treated as a dichotomous outcome
(dependent) variable with the following two levels: NEGATIVE for ADRB as determined in
objective bioanalytical confirmatory drug testing (NEGATIVE for all four statistics that comprise
the level, which are as follows, 1) presence of an illicit (PI), 2) presence of non-prescribed
medication (PNP), 3) absence of prescribed medication (AP), and 4) evidence of adulteration
(EA)); and POSITIVE, which was deemed as such if at least one of these statistics was positive.
2. Opioid Metabolism (OMS)
a. Conceptual definition – the pharmacokinetic biotransformation or conversion of the more
lipophilic opioid parent drug to a more water-soluble metabolite for excretion from the body.
7

Achieved through oxidation reduction and hydrolysis in phase I metabolism, and conjugation
reactions in phase II metabolism (Trescot, 2013; Trescot et al., 2008; Fishbain et al., 2004). For
the context of this study, emphasis was placed on the liver super family of microsomal enzymes
cytochrome P-450 (CYP450), specifically CYP2D6, which is responsible for catalyzing phase I
drug metabolism of important substrate opioids such as codeine, hydrocodone, oxycodone and
tramadol (Trescot et al., 2008).
b. Operational definition – Opioid metabolism or opioid metabolizer status (OMS) was
initially treated as an independent/predictor categorical variable, which consisted of the following
categories: 1) UM – ultra-rapid metabolizers (multiple copies of the CYP2D6 gene); 2) EM –
extensive metabolizers (a single wild-type copy of the CYP2D6 gene; 3) IM – intermediate
metabolizers (1 normal and 1 reduced allele, or 2 partially deficient alleles of the CYP2D6 gene);
and 4) PM – poor metabolizers (2 mutant alleles of the CYP2D6 gene leading to no detectable
enzyme activity). Dichotomization into normal metabolizer (NM) and variant metabolizer (VM)
levels was later performed to ensure adequate sample size and sampling ratio.
3. Therapeutic Failure/Toxicity
a. Conceptual definition – Therapeutic failure refers to the failure of chronic opioid therapy
to provide patients with meaningful reductions in pain. Often as the result of poor metabolic
conversion of a prodrug into its bioactive metabolite (Trescot & Faynboym, 2014; Gaedigk, 2013).
Toxicity relates to the group of opioid adverse drug reactions (such as constipation and respiratory
depression) that a chronic pain patient manifests from increased bioactive metabolite concentration
in the body – the result of increased metabolic enzyme activity.
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b. Operational definition – Mediating dichotomous variables with YES/NO levels derived
from Likert pain scales (dichotomized) and provider progress notes indicating adverse reactions
to prescribed medication.
In addition to the preceding variables, other categorical (race/ethnicity) and dichotomous
variables (gender, presence of CYP2D6 inducers/inhibitors) were included in the statistical models
to allow for control of confounding and effect modification.
1.5 Research Questions
The main question of the study is the following:
1) Among non-malignant chronic pain patients from an El Paso, Texas pain management
clinic, is there a statistically significant difference in the proportions of normal and variant
metabolizers on chronic opioid therapy that engage in aberrant drug-related behaviors?
Furthermore, it was of clinical value to seek answers to research questions that included
some of the potentially confounding variables (i.e. race, sex). The following two questions
illustrate this approach:
1. Among non-malignant chronic pain patients from an El Paso, Texas pain management
clinic, is there a statistically significant difference in the proportion of White and Hispanic patients
on chronic opioid therapy that engage in aberrant drug-related behaviors?
2. Among non-malignant chronic pain patients from an El Paso, Texas pain management
clinic, is there a statistically significant difference in the proportion of men and women on chronic
opioid therapy that engage in aberrant drug-related behaviors?
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1.6 Significance of the Problem – The Opioid Epidemic
One of the reasons why NMCPP on COT may display aberrant behaviors is the existence
of genetic polymorphisms that affect how quickly an opioid substrate is metabolized. The central
hypothesis in this study is that those individuals with variant expression of metabolizer enzymes
may end up supplementing (misusing, abusing, etc.) their medication with other prescribed drugs
and/or illicit substances to counteract the effects of therapeutic failure and/or toxicity. The misuse
of opioids is a major public health concern that goes beyond what I suggest here. It is problem of
enormous proportions, with profound health, social and financial implications for all Americans.
This opioid misuse “crisis” has intensified over the past couple decades. Major contributors to it
have been: a) the liberalization of laws governing the prescribing of opioids for the treatment of
non-malignant chronic pain by state medical boards, which has led to dramatic increases in opioid
use; b) the introduction in 2000 of new pain management standards by the Joint Commission on
the Accreditation of Healthcare Organizations (JCAHO, now the Joint Commission); c) the
increased awareness of the right to pain relief; d) the support from multiple organizations for the
use of opioids in large doses; and e) the aggressive marketing by the pharmaceutical industry,
which concealed and minimized the addictive characteristics of these drugs (National Institute on
Drug Abuse, 2017; Skolnick, 2017; Manchikanti et al., 2012).
According to the 2015 National Survey on Drug Use and Health (NSDUH), there were
approximately 91.8 million adults aged 18 or older who had used prescription pain medication;
this represents more than one-third (37.8%) of the adult population in the United States (Lipari,
Williams, & Van Horn, 2017; SAMHSA: Arthur Hughes, Matthew R. Williams, Rachel N. Lipari,
and Jonaki Bose & RTI International: Elizabeth A. P. Copello and Larry A. Kroutil, September
2016; Center for Behavioral Health Statistics and Quality, 2016). Furthermore, the proportion of
10

those who misused the medication was 12.5 million, 2.1 million misused it for the first time, 2
million had a prescription for opioid use disorder (OUD), and 828,000 abused heroin (SAMHSA,
January 25, 2017; SAMHSA, July 25, 2017; Lipari et al., 2017; National Institute on Drug Abuse,
2017; SAMHSA: Arthur Hughes, Matthew R. Williams, Rachel N. Lipari, and Jonaki Bose & RTI
International: Elizabeth A. P. Copello and Larry A. Kroutil, September 2016). In the same year
(2015) 33,091 died from overdosing on opioids, 9,580 died from overdosing on synthetic opioids
such as fentanyl, and 12,989 died from overdosing on heroin; the associated cost to society was
$78.5 billion (Centers for Disease Control and Prevention, 2015; NIDA, 2015; Manchikanti et al.,
2012; Leider, Dhaliwal, Sklar, & Kulakodlu, 2010). The United States is in the midst of a
significant crisis; 90 Americans die on a daily basis after overdosing on opioids (National Institute
on Drug Abuse, 2017), yet, its therapeutic use continues to escalate quadrupling since 1999
(Adams, Bledsoe, & Armstrong, 2016; Manchikanti et al., 2012). It is important to note that there
are still situations where patients who suffer from chronic pain legitimately benefit from
responsible and conservative prescribing, which integrate adequate monitoring and counseling
approaches. Most of the approximately 91.8 million adults who used opioid medication in 2015,
did so responsibly. The scale of the problem; product of irresponsible overprescribing, a
widespread notion that all you need to do to quickly address an underlying condition is to “pop a
pain pill” , and the pharmaceutical industry’s willful dishonesty in the late 90s; suggests that even
being a relatively low proportion, by sheer numbers, those who do misuse and abuse opioid
medication are still a substantially large number of all Americans (National Institute on Drug
Abuse, 2017; Adams et al., 2016). In October of 2017, the federal government finally addressed
the opioid epidemic by declaring it a top priority and outlining a comprehensive evidence-based
opioid strategy that leverages the expertise and resources of all the agencies from the Department
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of Health and Human Services (NIDA, 2018). The aims of this five-point opioid strategy are as
follows: 1) Improve access to prevention, treatment, and recovery support services, 2) Target the
availability and distribution of overdose-reversing drugs, 3) Strengthen public health data
reporting and collection, 4) Support cutting-edge research that advances our understanding of pain
and addiction, and 5) Advance the practice of pain management (NIDA, 2018). This dissertation
study contributed to these initiatives by presenting novel research data that advances the practice
of pain management while providing insight about the assessment of opioid risk and responsible
opioid prescribing.
1.7 Significance of the Study
Amid rising public concern for the devastating effects that the opioid epidemic is having
all across the United States (i.e. overdose deaths, loss of quality of life, increased cost to society),
the significant increase in opioid abuse and misuse over the past couple of decades, and, at the
other end of the spectrum, the “opiophobia” displayed by many medical professionals for fear of
the very real threat of litigation; there is now a substantial number of chronic pain patients that go
untreated, undertreated or poorly managed when they could have benefited from responsibly
implemented opioid therapy. Hence, the importance of recognizing that prescription opioid
medication continues to play a vital role in the treatment of non-malignant chronic pain.
Furthermore, prescribing opioids requires that proper risk assessment procedures be performed on
patients that are candidates for COT to substantially reduce the likelihood of opioid-related
aberrant behavior. To contribute to the improvement of risk assessment, this study sought to
describe whether a statistically significant association existed between OMS and ADRB. If such
an association had been significant, it would have supported the theoretical foundation for a new
COT ADRB risk assessment tool guided by objective biometric data rather than the more
12

subjective information currently available from the SOAPP-R and COMM questionnaires. The
new tool would have been of considerable clinical value to pain management practitioners since it
would have enabled the use of CYP2D6 genotypic data as a predictor of ADRB. Finally, the data
generated in the study could have been feed into protocol algorithms within LIS Decision Support
Systems to streamline this patient risk stratification process.
1.8 Assumptions
a. Based on the review of the literature, it was assumed that the independent/exposure
variable is comprised of levels from one cytochrome P250 enzyme only (CYP2D6), when in fact
several enzymes are involved in the metabolism of the same drug. Yet, previous studies justified
the approach in the context of this study as the opioids of interest (codeine, hydrocodone,
oxycodone & Tramadol) were primarily metabolized by CYP2D6.
b. The conceptual framework presented in this dissertation project assumed that variant
opioid metabolism dictated whether NMCPP experienced therapeutic failure or significant
toxicity, which then potentially lead to ADRB. Yet, opioid therapy failure/toxicity was not
necessarily a function of metabolizer status, nor metabolizer status was solely related to the genetic
mutations that affect the activity of metabolizing enzymes. Opioid metabolizer status is only one
of the reasons (albeit disproportionately significant) as to why patients may experience therapeutic
failure and/or toxicity. Some of other reasons include variant expression of transporter proteins,
variant expression of opioid receptors sites, genetics-induced variation in signaling for pain
perception, etc. Additionally, exogenous compounds (such as some anticonvulsants and some
antidepressants) can induce or inhibit the activity of opioid metabolizing enzymes (Trescot et al.,
2008).
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1.9 Limitations
Metabolism of the drugs of interest in this study undergo metabolic biotransformation by
enzymes and substances other than just CYP2D6, the enzyme that was being targeted here. Since
retrospective cohort studies are particularly susceptible to confounding (Sullivan, 2012), there
might have been other significant confounders that were not accounted for in the study (pain type,
pain location, COT duration, age range, and others were proposed as suspect confounding
variables for future studies). Use of a non-probability convenience sample in place of true random
probability sampling could have prevented adequate population representation and reduced
generalizability (Sullivan, 2012; Kaplan & Saccuzzo, 2009). Though, the main variables in the
study (OMS and ADRB) were treated as risk/exposure and an outcome variables, which may imply
causation, the goal was to only establish a potential association between these variables as there is
no experimental intervention. These limitations had the potential to restrict the interpretation and
generalizability of the findings in this study.
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CHAPTER 2

REVIEW OF THE LITERATURE
2.1 The Intersection of COT, ADRBs and Adherence Monitoring (Definitive Testing through
LC-MS/MS)
Chronic non-malignant pain management makes use of COT as one of the modalities to
relieve pain. Opioid medication adoption has increased dramatically over the past decade as
observed between the period from 2000 to 2002 when it increased by more than 200% (Peppin et

al., 2012). Peppin and colleagues (2012) indicated that Americans represent 4.6% of global
population yet consume 80% of the global opioid supply and two thirds of the world’s illicit drugs
(Peppin et al., 2012). With the increase in the prescription of opioids, there has been a welldocumented increase in its the misuse, abuse and diversion (Christo et al., 2011; L. Webster, 2010;
Chou, Fanciullo, Fine, Adler et al., 2009). Furthermore, while clinical experience suggests that
opioid medication does improve pain and functional status for some patients, some patients only
exhibit minimal improvement, and others will develop conditions such as endocrinopathies,
constipation, immunosuppression, sleep-disordered breathing, hyperalgesia, and addiction – ADR
and ADRB (L. Webster, 2010; Chou et al., 2009). All these potential behavioral and physiological
consequences make the use of opioids somewhat controversial in the treatment of non-malignant
chronic pain creating the need for tools to identify and monitor for aberrant drug-related behaviors
(Owen et al., 2012; Peppin et al., 2012; Christo et al., 2011; Webster, L., 2010; Chou et al., 2009;
Manchikanti et al., 2004). Urine drug testing (UDT) is at present one of the most objective
assessment tools in pain management for regimen compliance and detection of illicit drugs. In
addition, UDT facilitates the pharmacokinetic assessment of opioid clinical status (accomplished
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through the evaluation of relative proportions between parent drugs and their respective
metabolites). UDT offers pain practitioners and patients several advantages: it is relatively costeffective, widely available, and relatively well understood (when compared to other matrices)
while providing adequate detection windows. Furthermore, UDT urine specimens are very easily
collected, and the testing itself may serve as a deterrent for the abuse-prone patient (Lee & Zhang,
2013; Christo et al., 2011).
Naturally occurring/semi-synthetic opioid/opiate alkaloids such as codeine, hydrocodone,
oxycodone and tramadol along with their phase I metabolites (CYP2D6 metabolism), morphine,
hydromorphone, oxymorphone and O-Desmethyltramadol, are commonly used (as components of
COT) in the treatment of moderate to severe chronic pain due to their activity as μ-opioid receptor
agonists. (Christo et al., 2011; Manchikanti et al., 2004) Nevertheless, the benefits of this approach
must be weighed against the risk for adverse drug reactions (ADR) and the subsequent potential
for ADRB such as misuse and abuse of opioid drugs, and/or illicits. For instance, the prevalence
of illicit marijuana abuse among NMCPP is estimated to be around 15%, the highest compared to
other illicits. However, it is believed that in some contexts, marijuana use is linked to supplemental
pain relief to counteract the effects of therapeutic failure (Reisfield, Wasan, & Jamison, 2009;
Cone, Caplan, Black, Robert, & Moser, 2008).
2.2 Opioid Metabolism and Response
Drug metabolism and how it affects drug efficacy have become increasingly relevant in the
realm of pain medicine. Genetic polymorphisms may predict how well a drug will help a patient
attain pain relief or whether therapeutic failure and/or drug toxicity could occur. Moreover, clinical
evidence suggests that genetic differences may explain an estimated 20-95% of the variability in
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medication efficacy (Gupta, Hussainzada, & Del Tredici, 2014). This indicates that
pharmacotherapy can benefit from a tailored approach through metabolizer status information
(pharmacogenetic testing) that results in improved drug effectiveness and a reduction in the
potential for ADR. CYP2D6 gene polymorphism has been significantly implicated in drug
response variability, particularly for codeine, hydrocodone, oxycodone and tramadol (Crews et al.,
2014; Trescot & Faynboym, 2014). Furthermore, there are more than 100 different CYP2D6 alleles
that may affect enzyme activity and medication response but that still need formal evaluation in
clinical trials to ascertain their impact (Crews et al., 2014). Nevertheless, as depicted in Table 1,
allele variability does appear to account for metabolizer status differences as demonstrated by a
variety of allele diplotypes associated with multiple phenotypes (Crews et al., 2014).
Table 1. Examples of CYP2D6 genotypes and phenotype classification.
Allele 1

Allele 2

CYP2D6
Diplotype

CYP2D6
Activity Score

Phenotype

*1

*1xNa

*1/*1xN

≥3.0

UM

*2x2b

*41

*2x2/*41

2.5

UM

*1

*2

*1/*2

2.0

EM

*1

*17

*1/*17

1.5

EM

*2

*3

*2/*3

1.0

EM

*1

*4x2

*1/*4x2c

1.0

EM

*10

*10

*10/*10

1.0

EM

*4

*10

*4/*10

0.5

IM

*5

*6

*5/*6d

0

PM

Modified from Crews et al. (2014). Examples of CYP2D6 genotypes and phenotype
classification (Crews et al., 2014). EM: extensive metabolizer; IM: intermediate metabolizer;
PM: poor metabolizer; UM: ultra-rapid metabolizer.
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A retrospective study to assess abnormal PGT rates by Kirsh and colleagues (2014) (61
men and 41 women from a Louisiana pain clinic – average age of 46.7 years) classified 73.4% of
the patients as extensive metabolizers (EM), 11.4% as intermediate metabolizers (IM), 11.4% as
ultra-rapid metabolizers (UM), and 3.8% as poor metabolizers (PM) for CYP2D6 cytochrome
P450 enzyme. These results provide evidence that substantiates frequently encountered genetic
polymorphisms among NMCPP on COT (Kirsh et al., 2014). A study by Gupta et al. (2014) found
that CYP2D6 variant metabolizers (PM & UM) tend to exhibit poor clinical outcomes on
commonly used opioids such oxycodone and hydrocodone; and highlighted how this genetic
variation increases the risk for opioid dependence. The same study described how CYP2D6 PMs
experienced less analgesia than extensive metabolizers with oxycodone and hydrocodone in three
out of five well-validated pain tests. Finally, additional results showed that PMs had statistically
lower levels of oxycodone’s more analgesically potent metabolite oxymorphone (Gupta et al.,
2014). Several authors (Gupta et al., 2014; Trescot & Faynboym, 2014; Jannetto & Bratanow,
2009) referencing pharmacokinetic (a patient’s capacity for metabolizing drugs) and
pharmacodynamic (a patient’s ability to respond to a drug at a target or receptor site) principles
described how a PM may be unable to activate a prodrug such as codeine into its bioactive
morphine metabolite, while a patient with a non-functional mu-opioid receptor (OPRM1) would
not respond to that drug regardless of the dosage. These authors implied that polymorphic genes
encoding the drug-metabolizing enzymes (such as CYP2D6), drug transporters, drug receptors,
and other proteins could serve as useful biomarkers for predicting drug efficacy and potential for
ADR in human subjects (Gupta et al., 2014; Trescot & Faynboym, 2014; Jannetto & Bratanow,
2009). In their manuscript, Jannetto and Bratanow (2009) proposed that discrepancies in the
metabolism of opioid drugs can lead to therapeutic failure and/or toxicity by changing the
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relationship between the dose and plasma concentration of bioactive drug metabolites. They
explained that congenital alterations in the metabolism of opioid medication, and inherited
polymorphisms in drug receptor targets can have a greater impact on medication response than
any of the other clinical and physiological variables. They also indicated that while most
individuals are classified as EMs (metabolize affected drugs normally), 5-10% of Caucasians and
1-4% of most other ethnicities have decreased CYP2D6 activity (PMs) and may experience
reduced pain relief and/or toxic effects at clinical dosage (Jannetto & Bratanow, 2009). In
summary, by influencing the expression of drug metabolizing enzymes, drug transporters, opioid
receptors, and structures involved in the perception and processing of pain, genetics have an
important effect in the efficacy of opioid analgesics. (Trescot & Faynboym, 2014)
2.3 Pharmacogenetic Testing
Personalized medicine is increasingly becoming an important aspect to consider in the
practice of pain management and is now expected that providers tailor their therapy approach to
each patient. An example of this growing trend is pharmacogenetic testing (PGT), which helps
clinicians modify and optimize medication therapy to a patient’s genetic profile. Furthermore,
because PGT provides information on medication response, rather than disease risk or
vulnerability, it is now considered a more clinically actionable aspect of precision medicine (Gupta
et al., 2014). Besides the potential to improve health outcomes through better prediction of
medication response, PGT can also have significant economic benefits such as reducing the costs
associated with ADR (short term), and through health care savings from targeted drug treatments
(long term) (Gupta et al., 2014). Haga and colleagues (2013) described how PGT could have a
direct effect on the patient’s psyche to positively influence medication regimen adherence. They
found that when patients learn about their own genetic likelihood of having a positive therapeutic
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response or not experiencing an ADR from their medication, their perceived drug efficacy
increased while their level of concern diminished. Additionally, they also make a case for some of
the same potential benefits described by Gupta et al. (2014) for using PGT; reduced cost burden
associated with less medication trial and error and a significant reduction in the follow-up care
required for the management of ADR (Haga & LaPointe, 2013). Ultimately, PGT optimizes the
treatment for pain management. For instance, Janneto & Bratanow (2009) discussed how CYP2D6
genotyping through PGT could predict initial opioid therapeutic concentrations by patient
metabolizer status and identify individuals more likely to experience ADR when started on
standard dosage. This genetic knowledge on a patient not initially known to have variant
expression of CYP2D6 (i.e. PM) resulted in revised approaches where prescribers initiate opioid
therapy at a lower/higher dose relative to standard dosage to compensate for abnormal metabolism.
Furthermore, this patient could now be placed on substitute medication not affected by this
particular metabolic pathway (i.e. therapy with fentanyl instead of hydrocodone) (Jannetto &
Bratanow, 2009).
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2.4 CYP2D6 & Hydrocodone

Figure 2. CYP2D6 mediated transformation of hydrocodone to hydromorphone (Stauble et al.,
2014). Hydrocodone transformed via O-demethylation by CYP2D6 enzyme into
bioactive hydromorphone, which has a 10 to 33-fold greater affinity to μ-opioid
receptors.

Of interest to the study due to its frequent use in the treatment of moderate-to-severe
chronic pain is the semi-synthetic opioid pro-drug hydrocodone. As depicted in figure 2,
Hydrocodone is bio-transformed via O-demethylation by CYP2D6 into bioactive hydromorphone,
an opioid metabolite that has a 10 to 33-fold greater affinity to μ-opioid receptors and significantly
higher potency than its parent drug (Crews et al., 2014). A study on pharmacodynamic efficacy by
Stauble and colleagues (2014) demonstrated how pain relief is highly correlated to plasma
hydromorphone steady-state concentration (Css). This finding supports the pro-drug/bioactive drug
hydrocodone conversion theory in which hydrocodone’s metabolite concentration, not
hydrocodone dosage, influences therapy effectiveness (Stauble et al., 2014). Moreover, the study
emphasized the role that polymorphic CYP2D6 genotype plays in the efficacy of hydrocodone and
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other opioid medication. For instance, PM produce lesser amounts of the bioactive metabolite
hydromorphone, irrespective of hydrocodone dose. A separate test in the same study produced a
statistically significant inverse association (negative correlation) between plasma hydromorphone
Css and self-reported pain (Stauble et al., 2014). However, there was some evidence of CYP2D6
metabolizer status not affecting response to hydrocodone on PM, and little or no evidence of
increased hydrocodone response in CYP2D6 UM. The study concluded that there is insufficient
evidence to determine whether PM can be expected to have decreased pain relief, or whether UM
have increased risk of toxicity with standard doses of hydrocodone (Stauble et al., 2014). In a case
study by Susce et al. (2006), an 85-year-old Caucasian female patient with hip surgery and longstanding intolerance to codeine, oxycodone and tramadol (CYP2D6 substrates) received a second
round of opioid therapy with hydrocodone (another CYP2D6 substrate) that yielded a substantially
better response even though she had been phenotyped as a CYP2D6 PM (Susce, MurrayCarmichael, & de Leon, 2006). There was, however, no mention of concomitant use of CYP2D6
inducing/inhibiting medication that could have explained the discrepancy. This information seems
to similarly contradict the general consensus that variability in CYP2D6 genotype plays a
significant role in the metabolism of several opioid drugs and influences their pain alleviating
effects (Trescot & Faynboym, 2014).
While the importance of metabolizer status in the therapeutic effectiveness of hydrocodone
and other opioid alkaloids has been well established, it is also important to note that several other
genetic factors influence medication response. For instance, Trescot and Faynboym (2014)
reported on several well-studied hereditary disorders such as “hereditary insensitivity to pain with
anhydrosis”; they described some 200 candidate genes believed to be significantly implicated in
pain signal processing (Trescot & Faynboym, 2014). Moreover, certain substances can both inhibit
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and promote metabolizer enzyme activity. For example, CYP2D6 inhibitors such as quinidine,
paroxetine, fluoxetine and bupropion can affect EM and IM phenotypes making them appear like
a PM phenotype at normal dosage levels. (Susce et al., 2006)
2.5 Therapeutic Failure & (Pro-Drug/Metabolite) Toxicity
Several recent studies demonstrated that there is an important relationship between
polymorphic CYP2D6 (OMS) and medication response for common opioids such as hydrocodone
(Stauble et al., 2014; Jannetto & Bratanow, 2009; Haile, Kosten, & Kosten, 2008; Gan, Ismail,
Adnan, & Zulmi, 2007). Most of the research from these studies focused on slower CYP2D6
metabolizers (PM) and on some of the other CYP2D6 substrates (codeine and tramadol), as well
as hydrocodone. One study found a statistically significant association between plasma
concentrations of bioactive metabolite (hydromorphone) and pain relief, but no association
between pain relief and parent drug dosage (hydrocodone), which suggests a lesser role for the
CYP2D6 enzyme while it emphasizes the consideration of alternative medications for patients
identified as variant metabolizers (Stauble et al., 2014). A similar study that tested the relationship
of plasma Css for hydrocodone, tramadol, codeine and methadone with ADR reported that out of
all the patients who experienced ADR, four out of five (80%) had variant CYP2D6 metabolism
based on their predicted CYP2D6 phenotype (Jannetto & Bratanow, 2009). Another study by Gan
and associates (2007) conducted on Asians who had been prescribed tramadol found that IM
patients (none of the subjects in the study were PM so IM were used instead as the closest slower
metabolizer group) have a statistically higher incidence of ADR when compared to those that
metabolize tramadol faster (UM and EM patients). Additionally, CYP2D6*10 was identified as
the allele contributing the most to the incidence of intermediate metabolism among Asians (Gan
et al., 2007). Finally, Haile and colleagues (2008) reported on two very interesting findings that
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once again highlight the importance for the role of genetics in opioid response; first, that a group
of CYP2D6 PM Caucasians appeared to be protected from developing opioid dependence; and
second, that UMs tended to do poorly on methadone maintenance, and experienced frequent
withdrawal symptoms (Haile et al., 2008).
2.6 Bioanalytical Methodologies
2.6.1 Pharmacogenetic Testing
As previously described, pharmacogenetic testing (PGT) is a type of genetic test that
assesses a patient’s individual response to a given drug, to include the risk of an adverse reaction,
and provides information about optimal drug selection and dosing (Belfer, 2015; Kapur, Lala, &
Shaw, 2014; Mills, Voora, Peyser, & Haga, 2013; Stone & Bornhorst, 2012). For tailored opioid
therapies, PGT provides information on patient drug metabolizer status, receptor site expression
and information on the genetic aspects of pain perception to predict opioid efficacy and/or potential
for toxicity (Trescot & Faynboym, 2014). PGT is performed with molecular diagnostic and nucleic
acid detection techniques that enable the sequencing of complex genomes (Sawyer, 2015). These
techniques involve the selection and amplification of the nucleic acid of interest, the visualization
of the amplified nucleic acids, and the identification and quantification of individual nucleic acid
species (Sawyer, 2015). These processes are accomplished using the following analytical
methodologies:
1.- Polymerase Chain Reaction (PCR): A DNA technique that amplifies a single copy or
copies of a segment of DNA across several orders of magnitude to produce thousands to millions
of copies of that particular sequence. It makes use of a thermostable DNA polymerase, the
deoxynucleotides of each base (collectively referred to as dNTPs), the target sequence (the
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sample), and a pair of oligonucleotides (referred to as primers) complementary to opposite strands
flanking the sequence to be amplified. The process takes place over repetitive cycles of
denaturation, annealing, and extension that are paced by thermal cycling (Sawyer, 2015).
Assay method: First, target duplexes are denatured into single strands by heat. Upon
mixture cooling, primers provided in great excess will anneal to specific complementary sequences
on the target. After primer annealing, polymerases synthesize two additional DNA strands
containing the primers as the 5’ ends. The primers are then placed close enough together so that
the polymerase extends each strand far enough to include the priming site of the other primer.
Temperature cycling occurs as follows: 1) a high temperature to denature the target sequence, 2)
a low temperature that allows annealing of the primers to the target, and 3) a third temperature that
is optimum for polymerase extension (Sawyer, 2015).
2.- Microarray (also called DNA arrays, DNA chips, or biochips): A solid-phase
hybridization multi-plex 2D array assay for high-throughput quantification in which singlestranded nucleic acids form specific double-stranded hybrids. The process requires that both solidphase probe and target nucleic acids are mixed under conditions that allow for complementary
base pairing, and that there is a method to detect any resulting double-stranded nucleic acids.
Microarrays can assay large amounts of nucleic acids due the high density of their miniaturized
spot sizes (typically less than 200 microns in diameter) and are useful for testing multiple
mutations in genetic disease, oncology, and pharmacogenetics. They are also used to monitor the
whole genome for single-nucleotide variants (SNVs), gene expression, and copy number variants
(CNVs) (Sawyer, 2015).
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2.6.1.1 Pharmacogenetic Testing Sample Collection
The following steps describe the proper procedure for the collection of cheek swab samples
for pharmacogenetic testing that were carried out on the patients included in this study. This
procedure minimizes the risk of contamination with foreign DNA material (Millennium Health,
2017).
1. Open package and remove collector without touching sponge tip.
2. Place sponge as far back in the mouth as comfortable and rub along the lower gums in a
back and forth motion.
3. Gently rub the gums at least 10 times. If possible, avoid rubbing the teeth.
4. Gently repeat rubbing motion on the opposite side of the mouth along the lower gums for
an additional 10 times.
5. Hold the tube upright to prevent the liquid inside the tube from spilling.
6. Unscrew the cap from the collection tube without touching the sponge.
7. Turn the cap upside down, insert the sponge into the tube and close cap tightly.
8. Invert the capped tube and shake vigorously 10 times to mix fluid completely.
2.6.2 Toxicological Testing (Urine Drug Testing)
UDT is divided into two separate analytical chemistry techniques: enzyme immunoassay
(EIA) in the presumptive or screening phase (low specificity and sensitivity), and liquid
chromatography tandem mass spectrometry (LC-MS/MS) in the definitive or confirmatory phase
(high specificity and sensitivity).
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2.6.2.1 Presumptive Testing
Immunoassay testing is an analytical biochemical technique based on the binding reaction
of an antibody that is specific to the analyte of interest (i.e. a test drug) an that allows for the
detection of its presence and quantitation (A. Pesce et al., 2011). In enzyme-labeled immunoassays
(EIA), also called enzyme-linked immunosorbent assay (ELISA), an enzyme is chemically
attached (conjugated) to the labeled antibody. Like antibodies, enzymes are proteins that bind to
specific targets, but enzymes also catalyze specific reactions. The starting material for an enzymecatalyzed reaction is called a substrate. Enzyme labels, with the appropriate substrate, can be used
to generate color or create fluorescent or luminescent end products, which can be readily measured
by optical and electronic equipment. Each molecule of enzyme can convert many molecules of
substrate, providing a sensitive signal generation system (Wild, 2013). EMIT or Enzyme
multiplied immunoassay technique is a homogeneous immunoassay method for qualitative and
quantitative determination of drugs and certain proteins in serum and urine. The most widely used
applications for EMIT are for therapeutic drug monitoring (serum) and as a primary screen for
abused drugs and their metabolites (urine). Unlike ELISA, EMIT assays were developed in such
a way as to not to require a separation of bound component. Thus, if a high concentration of sample
analyte is present, this sample analyte will bind a large portion of antibodies leaving a large portion
of the analyte-bound enzymes free in solution. Conversely, if a low concentration of sample
analyte is present, this small concentration will bind only a small portion of the antibodies, leaving
a large portion of the antibodies to bind the analyte-bound enzymes and deactivate them (Wild,
2013).
There are important advantages to immunoassay (IA) for drug testing in serum and urine.
For testing that takes place within a pain management setting, immunoassay testing exhibits high
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levels of agreement for cocaine and other illicits (when compared to results from confirmatory
assays), and overall adequate sensitivity but at the expense of decreased specificity. Furthermore,
point-of-care (POC) devices provide a quick and inexpensive way to acquire initial patient insight
while instrument-based IA affords increased specificity and semi-quantitative data results
(Nafziger & Bertino Jr, 2009). However, immunoassays are subject to interference that may
produce both false-positive and false-negative results (Dasgupta & Ebooks Corporation, 2012).
An example of these limitations can be seen in urine drug testing for chronic pain patients; enzyme
immunoassay (EIA) drug profiles do not have proper cutoff levels to allow for detection of small
quantities of opioids. Other EIA profiles cannot detect certain parent drugs nor their metabolites
(i.e. semi-synthetic and synthetic opioids). In addition, individual drugs within a class may not be
identified nor differentiated (McBane & Weigle, 2010). In two separate studies, Pesce & Mikel et
al. (2012) reported on the limitations of EIA UDT, first in a diagnostic accuracy (DA) study where
they found false negative rates of 28% and 50% for benzodiazepine and cocaine respectively, and
on a second DA study for benzodiazepines only, where they reported false negative rates of 20%
(Mikel, Pesce, Rosenthal, & West, 2012; A. J. Pesce, Mikel, Rosenthal, & West, 2012).
2.6.2.2 Definitive Testing
There are a number of confirmatory methodologies for the quantification of drugs of abuse
including but not limited to: (1) gas chromatography (GC), (2) liquid chromatography (LC), (3)
GC/mass spectrometry (GC/MS), (4) LC coupled to MS (LC/MS), (5) GC with tandem MS
(GC/MS/MS), and LC with tandem MS (LC/MS/MS) (Center for Substance Abuse Treatment,
2012).
Chromatography is a process by which the components of a mixture are separated by
differential distribution between a mobile phase and a stationary phase. Components with greater
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distribution into the stationary phase are retained and move through the system more slowly
(Burtis, Ashwood, Bruns, & Tietz, 2012). In liquid column chromatography (figure 3) (LC and
GC belong to the column chromatography category as opposed to planar chromatography), a
sample injected into the mobile phase travels through a column that is packed with a stationary
phase composed of irregularly or spherically shaped particles, a porous monolithic layer, or a
porous membrane (Burtis et al., 2012).

Figure 3. LC setup diagram. File used under the Creative Commons Attribution-Share
Alike 3.0.

As the mixture of sample, matrix and solvents (mobile phase) moves forward, compounds with
strong interactions with the stationary phase will exhibit longer retention times and therefore will
elute in a different order of time (Fanali, Haddad, Lloyd, Poole, & Schoenmakers, 2013; Snyder,
Kirkland, & Dolan, 2010; Niessen, 2006). Figure 4 depicts this process.
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Figure 4. Chromatography column depicting separation of a complex matrix. From left to right,
Multiple compounds species (different colored dots) separate by differential affinity to
stationary phase (gray) and elute from column by different order of time.

LC employs the following separation techniques: Normal phase LC (polar stationary
phase, and a non-polar mobile phase), Reverse phase LC (opposite to normal phase LC, utilizes
non-polar stationary phase and polar mobile phase), Ion-pairing LC (performed on both normal
and reverse phase LC when analyte is relatively polar and hard to be retained. “counter-ion” used
for pairing), and Ion-exchange LC (stationary phase presenting ionizable groups that attract ions
with opposite charge through electrostatic interaction) (Fanali et al., 2013; Snyder et al., 2010,
Niessen, 2006;).
Mass spectrometry (MS) is a technique that identifies molecules by their mass to charge
(m/z) ratio. In MS, the sample containing the analyte is nebulized into an ion source; then,
together with the vaporized particles of other species in the sample it is ionized in the gas phase
through an ionization mechanism (i.e. electro spray ionization). The ions in the sample then enter
an electromagnetic field, the mass analyzer or mass filter, and get separated based on their m/z
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ratios. In the final stage, the separated ions are amplified by a detector (electron multiplier) and
the collection of their ion signals compose the mass spectrum (Burtis et al., 2012; Mondello,
2011; Niessen, 2006). The most common techniques for MS ion source ionization include:
chemical ionization (CI), electron impact (EI), electron spray ionization (ESI), and matrixassisted laser desorption ionization (MALDI). In tandem mass spectrometry (MS/MS), mass
spectra for both precursor (before fractioning by gas induced dissociation) and product ions
(after fractioning) is obtained in separate mass filters (Figure 5). m/z data from precursor and
product ions create a transition, a set masses specific to an analyte of interest (Hammett-Stabler
& Cotten, 2012).

Figure 5. Configuration of triple quadrupole MS. Tandem MS: 2 separate mass filters
separated by a gas collision cell. Curved yellow arrows represent filtered
compounds in first mass filter. Straight horizontal arrows represent selected
precursor and product ions, respectively. Vertical dotted arrow indicates the point
where collision-induce dissociation of precursor ion takes place. Curved blue
arrows represent filtered compounds in second mass filter.

While both LC-MS/MS and GC-MS provide great capabilities for identification and
quantitation of analytes (both offer enhanced selectivity (specificity) and sensitivity compared to
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other essays), LC-MS/MS offers advantages that are better suited for drugs of abuse testing
(Mikel et al., 2010).
These include:
•

The ability to discriminate a larger number of drugs in each test run.

•

The requirement of a very small amount of urine specimen (as little as 25
microliters, or one drop).

•

The use of samples that are neither derivatized nor extracted.

•

The capability to analyze hundreds of urine specimens per day on a single mass
spectrometer.

•

Through advances automated sample handling and bar coding, allowing for the
accurate processing of thousands of samples per day. This method of analysis can
provide results more rapidly than GC-MS.

•

Can accommodate non-volatile compounds (A. Pesce et al., 2011).

•

Can accommodate highly polar, high molecular-weight, or thermally labile
compounds (Marquet, 2012).

•

May offer improved specificity and lower limits of detection when compared
to other chromatographic methods (Dasgupta & Ebooks Corporation, 2012).

2.7 Summary
The purpose of the literature review in this study was to identify and summarize relevant
scientific literature that dealt with the topics of genetically-induced opioid metabolism (OMS), its
impact on medication effectiveness to relieve pain, and further associations to ADRB. It was also
an opportunity to offer more in-depth descriptions of the main bioanalytical methodologies used
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to generate the data for the study. The literature search portion focused on identifying available
evidence that associated opioid metabolism to adverse drug-related behaviors (misuse, abuse and
diversion). The initial alternative hypothesis proposed that an association between variant opioid
metabolism and therapeutic failure and/toxicity would lead to the association between variant
opioid metabolism and aberrant drug-related behaviors, but the literature review provided no
conclusive evidence to support this association. Nevertheless, it did reinforce the link between
OMS and medication response by findings of a significant relationship between variant CYP2D6
metabolizer status and response to opioid analgesic medication, which strengthened the resolve to
test further associations with ADRB.
The evidence identified in this review made strong correlations between genetic makeup
and the way in which different individuals experience pain relief when taking an opioid drug. This
connection validated what many patients had been communicating to their providers for many
years. It was vindication to them as we now understand that inter-individual variation in the
perception of pain and pain mitigation has a legitimate genetic component. In the context of the
present study, this finding took the form of a metabolizing enzyme (CYP2D6) whose geneticsdependent variability influences the effectiveness of opioid drugs on pain relief. The evidence
presented here made a compelling argument for this association. Several of the reviewed articles
further contributed to the argument by reporting that both poor and rapid (variant) opioid
metabolism resulted in either low or no pain relief, ADR from toxicity, or both, therapeutic failure
and toxicity. However, the literature search produced no evidence linking therapeutic
failure/toxicity to ADRB, nor evidence for the association between opioid metabolism (OMS) and
ADRB, the main focus of the review. It was therefore appropriate that these potential associations
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be explored and tested to increase our understanding of the factors that lead NMCPP on COT to
patterns of drug misuse and abuse.
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CHAPTER 3

METHODS
3.1 Study Design
A retrospective cohort study design was used to test the association between opioid
metabolism and ADRB. Records from an assembled (convenience) cohort of NMCCP on COT
were reviewed to retrospectively ascertain opioid metabolizer status and ADRB characteristics.
Retrospective categorical data (PGT/UDT and other non-PHI chart information) retrieved from a
Pain Management Clinic’s electronic medical records system was cross-tabulated and evaluated
with the Pearson Chi-square test for difference in proportions. There was no need for the Fisher’s
Exact test and/or Likelihood Ratio Chi-Square test as all expected cell counts were > 5. Logistic
regression was used to measure the contribution of confounders and to judge the presence of effect
modifiers (sex and race/ethnicity).
3.1.1

Design Justification and Applicability

Observational cohort studies involve groups of individuals who usually meet a set of
inclusion criteria but that differ by either possessing or not possessing a specific risk factor
(Sullivan, 2012). In general, individuals in a cohort study are followed in time to assess whether a
risk factor can be associated to an outcome such as a disease or a behavior (Sullivan, 2012).
Cohort studies can be further divided into prospective and retrospective studies, that is, by either
looking forward in time (ascertaining risk status and outcome prospectively) or looking back in
time (ascertaining risk status and outcome retrospectively) (Sullivan, 2012).
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Observation of NMCPP on COT in a an El Paso Pain Management Clinic seemed to
suggest that some patients experiencing adverse reactions could have been more inclined to misuse
their prescribed medication, abuse an illicit or engage in other aberrant behaviors to counter the
effects those adverse events. This informed the belief that variant OMS, a significant contributor
to therapeutic failure and toxicity, could be associated with incident ADRB. The clinic’s protocol
for the prescription of opioids included several measures to ensure safe drug administration and to
minimize the risk of addiction. Data initially generated as standard of care from two of these
measures, drug testing results and genetic testing results, was used to test the hypotheses in this
study. Since the data had already been collected on a relatively homogeneous group of patients, a
retrospective cohort study design was chosen. The association between risk factor (OMS) and
outcome (ADRB) was then evaluated with statistical testing.
Retrospective cohort studies can be affected by confounding and effect modification
(Creswell, 2009; Sullivan, 2012). Experience with patient behavior at the pain clinic suggested
that race/ethnicity and sex played an important role in ADRB. To counteract these effects, a
multivariate method (binary logistic regression) was used to estimate the association between
opioid metabolizer status (OMS) and ADRB adjusting for the impact of these confounding
variables (Hosmer, Lemeshow, & Sturdivant, 2013; Sullivan, 2012).
3.1.2 Variables
The study included two main variables for its primary hypothesis. There were three others
deemed to operate as mediating, confounding, and effect modifying variables. The main variables
consisted of opioid metabolizer status (OMS) and aberrant drug-related behaviors (ADRB), which
were considered a risk factor variable and an outcome variable, respectively. The potential
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mediating and confounding/effect modifying variables consisted of therapeutic failure/toxicity,
race/ethnicity, and sex, respectively.
1. OMS – the categorization of a patient’s metabolizing capability to pharmacokinetically
biotransform a lipophilic opioid parent drug to a more water-soluble metabolite for excretion from
the body. It is achieved through oxidation reduction and hydrolysis in phase I metabolism, and
conjugation reactions in phase II metabolism. (Trescot, 2013; Trescot et al., 2008; Fishbain et al.,
2004). In this study, emphasis was placed on the liver super family of microsomal enzymes
cytochrome P-450 (CYP450), specifically CYP2D6, responsible for catalyzing phase I drug
metabolism of substrate opioids such as codeine, hydrocodone, oxycodone and tramadol (Trescot
et al., 2008). This categorical variable was treated as a risk factor with the following levels: 1)
UM – ultra-rapid metabolizers (multiple copies of the CYP2D6 gene); 2) EM – extensive
metabolizers (a single wild-type copy of the CYP2D6 gene; 3) IM – intermediate metabolizers (1
normal and 1 reduced allele, or 2 partially deficient alleles of the CYP2D6 gene); and 4) PM –
poor metabolizers (2 mutant alleles of the CYP2D6 gene leading to no detectable enzyme activity).
2. ADRB – Patient misuse, abuse, overuse and diversion of licit and illicit drugs, as evidenced
on: urine toxicological testing by a finding of a positive illicit substance (i.e. metabolites of
marijuana,

cocaine

and

heroin),

positive

non-prescribed

medication

(i.e.

hydrocodone/hydromorphone), negative expected prescribed medication, and/or positive
adulteration/validity testing (i.e. pH, creatinine, oxidants); inter and intra-state prescription
monitoring program databases, which uncover evidence of doctor shopping; professional clinical
and psychological evaluation; self-admission, and evidence of dose escalation, amongst other
criteria (Peppin et al., 2012; Christo et al., 2011; Pergolizzi et al., 2010; Chou et al., 2009; L. R.
Webster & Webster, 2005). In this study, ADRB was treated as a binary outcome variable with
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the following levels: NEGATIVE for ADRB as determined in objective bioanalytical confirmatory
drug testing (must had been NEGATIVE for all four statistics that comprised each level: 1)
presence of an illicit (PI), 2) presence of non-prescribed medication (PNP), 3) absence of
prescribed medication (AP), and 4) evidence of adulteration (EA)) and a consistent PDMP; and
POSITIVE, which was deemed as such if at least one of these statistics was positive or the PDMP
was inconsistent.
3. Therapeutic Failure/Toxicity – Therapeutic failure referred to the failure of chronic opioid
therapy to provide patients with meaningful reductions in pain. Often as the result of poor
metabolic conversion of a prodrug into its bioactive metabolite (Trescot & Faynboym, 2014;
Gaedigk, 2013). Toxicity related to the group of opioid adverse drug reactions (such as
constipation and respiratory depression) that chronic pain patients experienced when the
concentration of a bioactive metabolite exceeded therapeutic levels – the result of increased
metabolic enzyme activity. This mediating dichotomous variable was to be accounted for in a
logistic regression model but was instead removed due to the very few records in our collected
sample that included the Likert scale and ADR information.
4. Race/ethnicity – categories included: Asian, Black, Hispanic, and White (National
Institutes of Health, 2015). Based on the observations of patients at the pain clinic, it was
reasonable to suggest that race/ethnicity was a potential confounder and/or effect modifier, and
thus, had to be accounted for in a logistic regression model.
5. Sex – consisted of two levels: Male and Female. As with race/ethnicity, empirical
observations pointed to a confounder and/or effect modifier role in the relationship between the
main study variables. Therefore, Sex was also be accounted for in a logistic regression model.
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3.2 Setting, Population and Sample
The setting for the study was a pain management clinic located in El Paso, Texas. Being
one of the largest in the region, the clinic saw an annual volume of approximately 15,000 patients
with non-malignant chronic pain. The main two treatment modalities offered at this clinic were
pharmacotherapy with adjuvant analgesics/opioid therapy; and interventional pain management
procedures such as epidural steroid injections, nerve blocks, facet joint injections, radiofrequency
nerve ablations, kyphoplasty, and spinal cord stimulators. Some of the conditions treated here
included the following: low back pain, radiating leg pain, knee pain, extremity pain, pelvic pain,
facial pain, acute or chronic back pain, back pain secondary to spondylosis/osteoarthritis, pain
from compression fractures, as well as acute/chronic musculoskeletal injuries (EPOSG, 2017).
The study population consisted of all the adult patients from an El Paso, Texas Pain
Management Clinic suffering from any kind of chronic pain of non-malignant origin (as indicated
in the ICD-10 diagnosis code (World Health Organization, 2015) or the provider’s progress note
in the patient’s chart), and who had, as treatment modality, been prescribed any opioid substrate
of the CYP2D6 metabolizing enzyme (i.e. morphine, hydrocodone, etc.) on a chronic basis (as
indicated on the provider’s progress note in the patient’s chart). This patient population
encompassed individuals of different race/ethnicities and sex.
The sample subset of the preceding population used in the study consisted of a nonprobability convenience sample of NMCPP on COT who meet the following inclusion criteria:
•

Patients of the clinic, male or female, of any race/ethnicity who are at least 18 years of
age, and;

•

had been diagnosed with any kind of non-malignant chronic pain,
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•

had been prescribed COT with one or several substrates of the CYP2D6 metabolizing
enzyme,

•

had signed an opioid treatment agreement,

•

had Texas PDMP (Texas State Board of Pharmacy, 2017) data retrieved recently,

•

had risk assessment/stratification performed with the SOAPP-R (Inflexxion, 2015),
and;

•

have had UDT/PGT performed in association with the COT regimen.

3.3 Sampling Procedures
The process to identify medical records that met inclusion criteria turned out to be
unexpectedly challenging and required a revision of strategy. Upon consultation with the clinic’s
pain physicians, Effect Size (ES) was revised to 0.13-0.15 (expected difference in proportions),
which allowed for a reduction in sample size to a target of 70 to 110 patient records for each cohort
while retaining critical values for significance and power (α = 0.05, 1-β = 0.80). One hundred and
eighty-six total patient records met all stipulated requirements (n = 186). However, due to the
extraordinary variability encountered in time elapsed to follow up office visits and drug testing (7
days to 3+ years), the initial protocol for identification of patient records with cohort matching
inter-visit times was eliminated. Furthermore, only the first visit (baseline) ended up having
enough collected data to competently evaluate incident ADRB and correlate it to the risk factors
included in the study. The second visit dataset had a considerable amount of missing UDT paired
values (n = 69); this eliminated the possibility of evaluating the study’s proposed associations for
the specified effect sizes at the second visit and was not used for any of the inferences drawn.
However, second visit statistical testing results, though suboptimal, were still compared to those
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of the initial visit to subjectively assess differences in patterns of opioid misuse, or changes in the
number of ADRB between these two visits.
3.4 Instrumentation
The biometric data included in the UDT and PGT reports was analyzed by highly specific
and sensitive validated analytical methods. Testing results to determine ADRB (positive/negative
for PI, PNP, AP & EA) were produced by analyzing a biological matrix (urine) in specialized
instrumentation at the toxicology laboratory of the clinic in the study, and at the laboratory of Alere
Toxicology, a partner of the pain clinic (Alere, 2017). For this study, an Agilent Technologies
6420 Triple Quad Liquid Chromatography Tandem Mass Spectrometry instrument or LC-MS/MS
(Agilent Technologies, 2013) was used to test for the presence of parent compounds and
metabolites of opioid medication and illicit substances, as well as for evidence of specimen
adulteration. Testing to evaluate OMS was conducted by several partner laboratories on cheek
swabs collected at the pain clinic. DNA testing methodologies, such as DNA extraction,
polymerase chain reaction (PCR), real-time PCR, PCR arrays, and PCR product electrophoresis
were used in instrumentation from various manufacturers to isolate genomic DNA, amplify it, and
analyze for deletions, duplications, and polymorphisms in the CYP2D6 cytochrome gene
(AltheaDx, 2017; AssureX Health, 2017; Millennium Health, 2017; PinPoint Molecular, 2017;
Proove Biosciences, 2017; Vantari Genetics, 2017; Dasgupta, 2007).
As advanced laboratory-developed methods (LDT), UDT and PGT methodologies
underwent extensive validation procedures that verify analytical performance and ensure that
testing quality is up to par for clinical testing in human subjects (CLSI, 2014; U.S. Food and Drug
Administration (FDA) & Center for Drug Evaluation and Research (CDER)). LDTs must be
reliable, valid and robust. A detailed multi-study method development and validation protocol was
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implemented to achieve these characteristics in the LC-MS/MS instrument that was used in the
study. This protocol involved studies that evaluated internal standard selection, sample preparation
and extraction; development and optimization of ion transitions; determination of mobile phases
and chromatography columns; verification of specificity, linearity, accuracy, precision
(reproducibility), reportable range, quantitation limits, and detection limits; evaluation of
interfering substances, matrix effects, ion suppression, and carryover; specimen stability;
hydrolysis optimization of glucuronide conjugates; and assessment of quality control material
(CLSI, 2014; U.S. Department of Health and Human Services U.S. Food and Drug Administration
(FDA) & Center for Drug Evaluation and Research (CDER)). There was no validation protocol
available for the methodologies from partner laboratories since LDTs are proprietary. However,
they all had to meet CLIA 88’ stringent criteria for LDTs in a high-complexity CLIA laboratory
setting, which, upholds their testing methods’ validity and reliability (COLA Accreditation
Program, 2016).
3.5 Data Collection
Patient medical record retrieval began on July 20 of 2018 and ended in July 27 of 2018.
All records corresponded to dates of service extending from January 2016 through March 2018.
The retrieval process entailed the collection of basic, non-PHI, demographic information (such as
Age, Sex and Race/Ethnicity) supplemented with a special study identifier (“Study ID”); initial
visit information (baseline pain scale, treatment agreement/informed consent for COT, baseline
risk assessment, baseline PMP, PGT, baseline UDT, and baseline CYP2D6 drug substrates and
inhibitors), subsequent visit information (most items from initial visit but no PGT and treatment
agreement/informed consent); and if available, information from a third visit (same information as
previous visit). There was a two-fold rationale for collecting data on initial and subsequent visits:
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1) the patient would have had to have received a prescription for opioid medication on their initial
office visit in order to detect a legitimate positive opioid drug test results at these subsequent visits.
This was required to inform ADRB assessments. However, upon review of the data, it was made
clear that almost all patients coming in to their first visit were already on COT; and 2) there was
evidence that repeated drug testing served as a deterrent for abuse-prone patients (A. J. Pesce et
al., 2011). A deterrent-induced reduction in UDT positivity rates had the potential to confound the
relationship between incident ADRB and OMS and merited further exploration across separate
office visits. Additionally, attempts were made to retrieve only those patient records that had, for
both OMS cohorts (normal and variant), similar time periods elapsed in-between office visits to
control for artificial confounding of UDT positivity rates. Yet, significantly high variability in
these inter-visit times made that approach extremely impractical.
3.5.1

Collection of Patient Urine Drug Testing Results

The Principal Investigator (PI) and his professional assistant (took CITI training for the
protection of human participants) retrieved approximately 70-100 individual drug testing patient
records for each cohort (n = 186) from either the clinic’s EMR: Prime Suite (Greenway Health,
2017), the clinic’s toxicology laboratory cloud-based information system (LIS): AxisLabsDX
(Alternative Biomedical Solutions, 2017), and/or the Alere Toxicology web portal: Alere Datalink
(Alere, 2017). Only pertinent variable data (opioid, illicits and adulterant results indicating PI,
PNP, AP & EA) along a non-PHI unifying identifier was extracted to an excel database.
3.5.2

Collection of Patient Pharmacogenetic Testing Results

The same procedure was applied to the retrieval of genetic testing data. However, in
addition to the sources mentioned above, data was also retrieved from the Millennium Health,
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AltheaDx, AssureX, Vantari Genetics, PinPoint Molecular and Proove Biosciences web portals
(AltheaDx, 2017; AssureX Health, 2017; Millennium Health, 2017; PinPoint Molecular, 2017;
Proove Biosciences, 2017; Vantari Genetics, 2017). Pertinent variable data (CYP2D6 metabolizer
status indicative of PM, IM, EM and UM) along non-PHI unifying identifier was extracted to an
excel database.
3.5.3

Collection of Patient Medication History and Demographic Information

Patient demographics to include age, sex, race/ethnicity; and other non-PHI relevant data,
such as date of service, diagnosis codes, and relevant instances of opioid medication prescription
were retrieved from the clinic’s own EMR: Prime Suite (Greenway Health, 2017), and extracted
to an excel database.
3.6 Data Analysis
3.6.1

Data Preparation

The PI was responsible for manipulating the data extracted to the excel database. Patient
data from various sources was consolidated for each patient record with the aid of unifying
identifiers. To ensure confidentiality, no protected health information (PHI) identifying individual
patients (i.e. name, date of birth) was retrieved and added to the study’s database spreadsheet.
After subsequent cleaning of variable data, secondary variables derived from primary data were
created to properly address the research questions and to further conceal personal identifiable
information. Such variables include: Outcome dichotomous variable: ADRB, with levels
NEGATIVE/POSITIVE; derived from confirmatory drug testing statistics PI, PNP, AP and EA,
that were themselves derived from individual drug/adulterant testing result reports; and PDMP
reports. Categorical risk variable: OMS, with four initial categories: UM, EM, IM and PM;
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transformed to a dichotomous risk variable, with levels NORMAL/VARIANT. EM phenotype
classified as normal OMS, and UM/PM/IM phenotypes classified as variant OMS. Transformation
was made to ensure adequate sample size and sampling ratio.
3.6.2

Statistical Analyses

The PI conducted all the statistical analyses required to address the research questions of
the study. In the first analysis, summary statistics were calculated on all the relevant variables of
the study and presented in frequency distribution tables (Sullivan, 2012). Next, hypothesis testing
was used to evaluate associations between variables and answer the study’s research questions.

I.

The primary hypotheses tested whether a statistically significant difference existed in the

proportions of normal and variant metabolizers that engage in ADRB in a group of NMCPP on
COT from an El Paso, Texas pain management clinic (Sullivan, 2012), where:
H0: There is no statistically significant difference in the proportion of normal and variant
metabolizers that engage in ADRB.
H1: There is a statistically significant difference in the proportion of normal and variant
metabolizers that engage in ADRB.
The test statistic used was χ2 (Chi-squared) test for difference in proportions at α= .05
(Sullivan, 2012). The cross-tabulation of risk and outcome variables, calculation of expected
frequencies, and computation of test statistic and odds ratios where performed in SPSS Statistics,
Version 24 (IBM Corp., 2016).

II.

The secondary hypotheses with race/ethnicity as the risk variable tested whether a

statistically significant difference existed in the proportions of White and Hispanic patients that
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engage in ADRB in a group of NMCPP on COT from an El Paso, Texas pain management clinic
(Sullivan, 2012), where:
H0: There is no statistically significant difference in the proportion of White and Hispanic
patients that engage in ADRB.
H1: There is a statistically significant difference in the proportion of White and Hispanic
patients that engage in ADRB.
The test statistic used was χ2 (Chi-squared) test for difference in proportions at α= .05
(Sullivan, 2012). The cross-tabulation of risk and outcome variables, calculation of expected
frequencies, and computation of test statistic and odds ratios where performed in SPSS Statistics,
Version 24 (IBM Corp., 2016).

III.

The last set of secondary hypotheses with sex as the risk variable tested whether a

statistically significant difference existed in the proportions of Males and Females that engage in
ADRB in a group of NMCPP on COT from an El Paso, Texas pain management clinic (Sullivan,
2012), where:
H0: There is no statistically significant difference in the proportion of Males and Females
that engage in ADRB.
H1: There is a statistically significant difference in the proportion of Males and Females
that engage in ADRB.
The test statistic used was χ2 (Chi-squared) test for difference in proportions at α= .05
(Sullivan, 2012). The cross-tabulation of risk and outcome variables, calculation of expected
frequencies, and computation of test statistic and odds ratios where performed in SPSS Statistics,
Version 24 (IBM Corp., 201612).
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IV.

Stepwise binary logistic regression analyses were conducted to account for confounding

and effect modification of the relationship between primary variables OMS and ADRB by suspect
variables “Sex” and “Race/Ethnicity”. Suspect mediating variable “Therapeutic failure/Toxicity”
was ultimately excluded from the study due to insufficient Likert pain scale records and
inconsistent provider progress notes indicative of adverse drug reactions. The computation of
regression statistics, odds ratios and confidence intervals was performed in SPSS Statistics,
Version 24 (IBM Corp., 201612).
3.7 Protection of Research Subjects
As a retrospective cohort study with no human participants/subjects, the risk of adverse
events was significantly low. Indeed, in its policy for protection of human research subjects, the
department of Health and Human Services stipulates that “unless otherwise required by department
or agency heads, research activities in which the only involvement of human subjects includes the
collection or study of existing data, documents and records are exempt from requiring internal
review board (IRB) approval” (U.S. Department of Health & Human Services, 2009). However,
an IRB exemption request application was submitted to UTEP’s IRB office to certify exempt status
and obtain explicit authorization to conduct the study. In addition, written authorization from the
clinic’s chief medical officer was obtained in order to access and retrieve patient record data from
the EMR. Even if exempt from IRB approval, patient confidentiality was rigorously maintained
throughout all phases of data collection and data analysis. All non-PHI patient record data retrieved
was “manually deidentified” by elimination of identifiers that in conjunction with other
information could be traced back to an patient, and, “statistically de-identified” by only presenting
aggregate data and summary/inferential statistics. Only the PI and his professional assistant had
access to the dataset. Data manipulation and statistical analyses were only performed on password47

protected devices (PPD). Aside from the PI’s secured portable device, data also resided on PPDs
at the clinic’s toxicology laboratory where access is highly restricted.
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CHAPTER 4

RESULTS
The purpose of this study was to lay the scientific foundation for the creation of a novel
biometric tool based on genetic information about the polymorphic expression of CYP2D6 for the
prediction of ADRB among NMCPP on COT. More specifically, the study’s objective was to
address the question of whether a statistically significant association existed between opioid
metabolism, as determined by phenotypic CYP2D6 expression (OMS), and aberrant drug-related
behaviors among non-malignant chronic pain patients. It also sought to address other research
questions evaluating the association of sex and race/ethnicity with ADRB. To test the study’s
hypotheses, retrospective categorical data from an assembled cohort of NMCPP on COT was
cross-tabulated and analyzed with the Pearson Chi-square test for difference in proportions.
Confounding and effect modification were dealt with by the inclusion of suspect variables in a
logistic regression model.
4.1 Descriptive Statistics
The median age in the sample population was 54 years old with an age range from 20 to
87 years old. Age data appears to be slightly skewed towards older age. Table 2 shows Age
descriptive statistics.
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Table 2. Descriptive statistics for Age.
Age
N

186

Mean

53.39

Median

54.00

Std. Deviation

14.143

Range

67

Minimum

20

Maximum

87

N = total sample size.

There were 104 (55.9%) females and 82 (44.1%) males from four race/ethnicity categories: 4
(2.2%) Asian, 10 (5.4%) Black, 103 (55.4%) Hispanic and 69 (37.1%) White. There were more
Hispanics than all other race/ethnicities combined (55% vs. 44.6%, respectively). Due to very low
representation (and to prevent bias) Asian and Black patient records were excluded from inferential
statistics. Tables 3 and 4 present frequency distributions and percents for Sex and Race/Ethnicity.

Table 3. Frequency distribution for Sex
Sex
Cumulative
Frequency

Percent

Valid Percent

Percent

Female

104

55.9

55.9

55.9

Male

82

44.1

44.1

100.0

Total

186

100.0

100.0
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Table 4. Frequency distribution for Race/Ethnicity
Race/Ethnicity
Cumulative
Frequency

Percent

Valid Percent

Percent

Asian

4

2.2

2.2

2.2

Black

10

5.4

5.4

7.5

Hispanic

103

55.4

55.4

62.9

White

69

37.1

37.1

100.0

Total

186

100.0

100.0

Sample frequency distribution for CYP2D6 phenotype categories was as follows: 101 (54.3%)
EM’s, 42 (22.6%) IM’s, 24 (12.9%) PM’s and 19 (10.2%) UM’s. As a convenience sample,
frequency distributions for variant OMS (PM, IM & UM) were much higher than in the patient
population where the sample was draw from (See Table 5).

Table 5. Frequency distribution for CYP2D6 Phenotype
CYP2D6 Phenotype
Cumulative
Frequency

Percent

Valid Percent

Percent

Extensive Metabolizer

101

54.3

54.3

54.3

Intermediate Metabolizer

42

22.6

22.6

76.9

Poor Metabolizer

24

12.9

12.9

89.8

Ultrarapid Metabolizer

19

10.2

10.2

100.0

Total

186

100.0

100.0
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4.2 Inferential Statistics
4.2.1 Opioid Metabolizer Status and Aberrant Drug Related Behaviors
A χ2 (Pearson Chi-squared) test for difference in proportions at α = 0.05 was conducted to
ascertain whether differences in proportions between OMS category levels predicted ADRB
incidence (H1). To address discrepancies in sample size for each of the CYP2D6 metabolizer
categories, OMS was dichotomized into Normal Metabolizer (NM = 54.3%), which included the
EM phenotype, and Variant Metabolizer (VM = 45.7%), which included the other three
phenotypes: PM, IM and UM. Table 6 shows the frequency distribution of the 2 independent
samples with a sampling ratio (κ) that is closer to 1 after OMS was dichotomized.

Table 6. Reorganization of CYP2D6 Phenotype (OMS) from categorical to binary.
CYP2D6 Phenotype
Cumulative
Frequency

Percent

Valid Percent

Percent

Normal Metabolizer (EM)

101

54.3

54.3

54.3

Variant Metabolizer (PM, IM or

85

45.7

45.7

100.0

186

100.0

100.0

UM)
Total
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The crosstabulation of OMS and baseline ADRB revealed very little discrepancy in incident
ADRB by level of OMS variable (NM = 32.7% vs. VM = 35.3%). Total ADRB incidence was
33.9%. (Table 7 depicts this and other crosstab data).

Table 7. Crosstabulation of OMS and ADBR (baseline)
CYP2D6 Phenotype (OMS) * ADRB (baseline)
ADRB (baseline)
Not Present

Present

Total

68

33

101

66.8

34.2

101.0

67.3%

32.7%

100.0%

55

30

85

56.2

28.8

85.0

64.7%

35.3%

100.0%

123

63

186

Expected Count

123.0

63.0

186.0

% within CYP2D6 EM &

66.1%

33.9%

100.0%

CYP2D6

Normal Metabolizer

Count

Phenotype

(EM)

Expected Count

(OMS)

% within CYP2D6 NM
Variant Metabolizer

Count

(PM, IM or UM)

Expected Count
% within CYP2D6 VM

Total

Count

VM

There was no statistically significant difference in proportions of incident ADRB (baseline)
between normal and variant opioid metabolizers [χ2 = 0.142, p = 0.707, α = 0.05]. Further
substantiation of this finding was offered by a 95% confidence interval for the odds of ADRB in
NM vs. that of VM which includes 1 [OR =0 .926, 95% CI (.620, 1.383)]. (Please see Table 8 for
Chi-squared statistics).
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Table 8. Chi-squared statistics for OMS *ADRB (baseline)
CYP2D6 Phenotype (OMS) * ADRB (baseline)
Asymptotic

Pearson Chi-Square
Continuity

Correctionb

Likelihood Ratio

Significance (2-

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

0.757

0.412

Value

df

sided)

0.142a

1

0.707

0.049

1

0.825

0.141

1

0.707

Fisher's Exact Test
Linear-by-Linear

0.141

1

0.708

Association
N of Valid Cases

186

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 28.79.
b. Computed only for a 2x2 table

Figure 6 below conveys the similarities of the relative proportions of incident ABDR between NM
and VM.

OMS*ADRB Baseline
80
70

68
55

Count

60
50
40

33

30

30

ADRB at baseline?
Not Present

20

Present

10
0
Normal Metabolizer (EM)

Variant Metabolizer (PM, IM
or UM)

CYP2D6 Phenotype

Figure 6. Bar chart depicting relative proportions of incident ABDR between NM and VM.
Normal metabolizer (NM) category is comprised of extensive metabolizers (EM),
whereas, variant metabolizer (VM) includes poor metabolizers (PM), intermediate
metabolizers (IM), and ultra-rapid metabolizers (UM).
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The information gathered from the second office visit was missing a substantial amount of
UDT data points, which rendered many patient records unusable. Sample size went down to n =
69. The sampling ratio (κ) remained close to 1 with each independent sample containing
approximately 35 patient records. Retaining critical values for significance and power (α = 0.05,
1-β = 0.80) made the model significantly less sensitive to smaller ES and less suitable for robust
statistical evaluation. Second visit distribution for incident ADRB by level of OMS was NM =
43.8% vs. VM = 45.9%. There was no statistically significant difference in proportions of incident
ADRB (second visit) between normal and variant opioid metabolizers [χ2 = 0.33, p = 0.855, α =
0.05]. Further substantiation of this finding would have been offered by a 95% confidence interval
for the odds of ADRB in NM vs. VM that includes 1 [OR = 0.952, 95% CI (0.563, 1.611)]. Tables
9 and 10 show Chi-squared and Odds Ratio statistics.

Table 9. Chi-squared statistics for OMS *ADRB (second visit)
CYP2D6 Phenotype (OMS) * ADRB (Second visit)
Asymptotic

Pearson Chi-Square
Continuity

Correctionb

Likelihood Ratio

Significance (2-

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

1.000

0.524

Value

df

sided)

0.033a

1

0.855

0.000

1

1.000

0.033

1

0.855

Fisher's Exact Test
Linear-by-Linear Association
N of Valid Cases

0.033

1

0.856

69

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 14.38.
b. Computed only for a 2x2 table
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Table 10. Odds ratio and 95% confidence intervals for OMS *ADRB (second visit)
OR and 95% CI for CYP2D6 Phenotype (OMS) * ADRB
(Second visit)
95% Confidence Interval

OR ADRB (2nd visit) = Present

Value

Lower

Upper

0.952

0.563

1.611

The total percentage of incident ADRB (both OMS levels) increased significantly from
first visit to the second visit, 33.9% vs 44.9%, respectively.
4.2.2 Sex and Aberrant Drug Related Behaviors
Crosstabs of Sex and ADRB (assessed on first and second patient visits) revealed patterns
like those of OMS first and second visit data – slight incidence discrepancies between OMS
categories and an incidence jump in ADRB from first to second visit. Incidences for ADRB, first
and second visits, were as follows: (Male = 37.8% vs. Female = 30.8%) and (Male = 41.7% vs.
Female = 48.5%), respectively. There was no statistically significant difference in proportions of
incident ADRB (baseline and second visits) between males and Females [χ2 = 1.013, p = 0.314, α
= 0.05] [χ2 = 0.323, p = 0.570, α = 0.05]. The 95% confidence interval for the odds of ADRB in
Male vs. Female included 1 [OR = 1.229, 95% CI (0.823, 1.833)] and [OR =0 .859, 95% CI (0.510,
1.449)] for baseline and subsequent visits, respectively.
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4.2.3 Race/Ethnicity and Aberrant Drug Related Behaviors
The Race/Ethnicity variable was dichotomized for inferential statistics by dropping two
low representation levels: Asians and Blacks. The crosstabulation of Race/Ethnicity and ADRB
(assessed on baseline and subsequent visits) followed previous ADRB incidence patterns.
Incidence for ADRB, first and second visits, were as follows: (White = 36.2% vs. Hispanic =
33.0%) and (White = 44.0% vs. Hispanic = 45.0%), respectively. There was no statistically
significant difference in proportions of incident ADRB (baseline and second visits) between
Whites and Hispanics [χ2 = 0.190, p = 0.663, α = 0.05] [χ2 = 0.006, p = 0.937, α = 0.05]. The 95%
confidence interval for the odds of ADRB in Whites vs. Hispanics included 1 [OR = 1.098, 95%
CI (0.724, 1.665)] and [OR = 0.978, 95% CI (0.559, 1.711)] in baseline and subsequent visits,
respectively.
4.2.4 Binary Logistic Regression for Confounding and Effect Modification
Stepwise binary logistic regression analyses were conducted to evaluate the relationship
between OMS and ADRB while adjusting for suspect variables “Sex” and “Race/Ethnicity”
individually and in combination. There was no statistically significant difference in the proportions
of incident ADRB (baseline) between normal and variant opioid metabolizers after adjusting for
Sex [(Sig.)p = 0.682, α = 0.05, OR[Exp(B)] = 0.880, 95% CI (0.478, 1.621)]. There was no
statistically significant difference in the proportions of incident ADRB (baseline) between normal
and variant opioid metabolizers after adjusting for Race/Ethnicity [(Sig.)p = 0.485, α = 0.05,
OR[Exp(B)] = 0.797, 95% CI (0.422, 1.506)]. There was no statistically significant difference in
the proportions of incident ADRB (baseline) between normal and variant opioid metabolizers after
adjusting for both Sex and Race/Ethnicity [(Sig.)p = 0.773, α = 0.05, OR[Exp(B)] = 0.938, 95%
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CI (0.608, 1.447)]. Table 11 presents the logistic regression statistics for the formal evaluation of
confounding and effect modification.
Tables 11. Logistic regression coefficients and statistics.
Logistic Regression Statistics*ADRB (baseline)
95% C.I.for EXP(B)
Step

B

S.E.

Sig.

Exp(B)

Lower

Upper

OMS/SEX*ADRB (baseline)

-0.128

0.312

0.682

0.880

0.478

1.621

OMS/RACE*ADRB (baseline)

-0.227

0.325

0.485

0.797

0.422

1.506

OMS/RACE/SEX*ADRB (baseline)

-0.064

0.221

0.773

0.938

0.608

1.447
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CHAPTER 5

DISCUSSION
Amid intensifying public concern for the devastating and very real effects that the misuse
and abuse of opioids are having in our communities across the country; the so called “Opioid
Crisis”, it is important to recognize that these are legitimate medications that help many people
when prescribed and taken responsibly. Widespread “opiophobia”, though justified, may in some
ways be contributing to the growing number of chronic pain patients who go untreated or
undertreated as medical professionals stop making the option of these drugs available to them.
Sometimes even out of fear for the very real threat of litigation associated with prescribing
narcotics. Prescription opioid medication continues to play a crucial role in the treatment of nonmalignant chronic pain. Reducing the likelihood of patients engaging in aberrant drug-related
behaviors such as opioid misuse requires the implementation of proper risk assessment procedures
for the safe and effective administration of these medications to those individuals who really need
them most.
The aim of this study was to test for statistically significant associations between opioid
metabolism and aberrant drug-related behaviors among non-malignant chronic pain patients. The
information gathered from the study would have served as the theoretical foundation of a new tool
for risk assessment that relies on objective biometric data. Currently, we largely base these
assessments on information drawn from survey instruments such as the SOAPP-R and COMM
(Inflexxion, 2015), which have the potential to be manipulated. This “improved” biometric tool
would have allowed pain practitioners to make use of genotypic data to better predict which
patients are at a greater risk of engaging in aberrant drug-related behaviors. Moreover, the data
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generated by the study could also be feed into protocol algorithms, such as patient risk
stratification, and incorporated into LIS Decision Support Systems.
The approach selected to meet the objectives of the study consisted of an evaluation of the
relationship between opioid metabolism, as determined by phenotypic CYP2D6 expression
(OMS), and aberrant drug-related behaviors (ADRB), in the population of interest. The specific
research questions to be answered were the following:
1. Among non-malignant chronic pain patients on COT from an El Paso, Texas pain
management clinic, is there a statistically significant difference in the proportions of normal and
variant metabolizers that engage in aberrant drug-related behaviors?
This was the central question of the study. Previous experience at a pain clinic and
discussions with providers informed the hypothesis that patients who are variant opioid
metabolizers, in particular poor metabolizers, seemed more inclined and willing to misuse their
medication or supplement with an illicit substance, when compared to normal metabolizers.
Statistical analysis revealed there is no statistically significant association between OMS and
ADRB. This answers the question, but not necessarily in the manner that was expected. In her
review on the role that genetics play in opioid metabolism, Trescot and colleagues (2014) pointed
out that the prevalence of variant CYP2D6 metabolism at its fringes (PM & UM) is around 17%
in the general population (Trescot & Faynboym, 2014). That is almost a fifth of all Americans who
could conceivably deal with therapeutic failure and/or toxicity at some point in their lifetime, and
whom you could have expected to be at a higher risk of misusing narcotic substrates of CYP2D6.
Yet, study data showed that this is clearly not the case with the clinic’s variant metabolizers as
they don’t appear to misuse medication at comparably higher rates. The pain clinic where this
study was performed has a similar prevalence of variant CYP2D6 metabolizers, 15% – 20%. We
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frequently encounter patients who experience adverse drug reactions (who later test as variant
metabolizers) that appear to misuse their opioid medication more often to counter those adverse
events. However, the results from this study seem to again suggest that if that was in fact true
(VMs misusing opioids more often), it happens just as often with normal metabolizers. An
interesting finding of the study was that the incidence of ADRB was a lot higher than expected,
33.9% at baseline visit. This would mean that, irrespective of 2D6 metabolizer status, 1 out of
every 3 patients in our sample population engaged in some kind of aberrant behavior. Perhaps the
inclusion as ADRB of inconsistencies with prescribed medications, non-prescribed licit
medications, and doctor shopping, in addition to positive illicits (all are just as clinically relevant
in pain medicine), revealed a more accurate picture of the incidence of these undesirable behaviors
among NMCPP, which may merit further exploration. Total ADRB incidence for the second visit
was even higher than that of the first, however, the sample size on the second visit was very small
(n = 69) due to missed UDT paired data. This makes inference from that data set highly unreliable
and was not used in the study’s conclusions even though the statistics are included in the results
chapter. The data collected on both the first (baseline) and subsequent visits showed a similar
ADRB incidence pattern for both cohorts, with slightly higher incidence in the VM cohorts (NM
= 32.7% vs. VM = 35.3%, and NM = 43.8% vs. VM = 45.9%; for first and subsequent visits,
respectively). While these findings appear to support the alternative hypothesis in the direction we
would have expected it to sway towards (high ADRB on VMs), first, the incidence difference was
shown to be statistically insignificant by sample data drawn from the first office visit, and second,
it could not have been corroborated by the statistically sub-optimal data from the second visit. The
assessment of confounding from the deterrent-induced reduction in UDT positivity rates for
subsequent visits [as described by Pesce et al. (2011)] was not performed due to the lack of paired
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UDT data in the second office visit and wild variation in inter-visit time frames, which is itself a
potential source of confounding. Future studies could aim at assessing confounding from this
phenomenon.
Race/Ethnicity and Sex were not just only important from the perspective of the impact
they might have had on the interaction between the primary risk variable (OMS) and the outcome
variable (ADRB) but were themselves of significant clinical value and merited individual
evaluation of a potential associations with ADRB. However, as initially hinted by the χ2 statistics
in Chi-squared testing, and confirmed in formal logistic regression analysis, Race/Ethnicity and
Sex do not confound or modify the association between OMS and ADRB.
2. Among non-malignant chronic pain patients on COT from an El Paso, Texas pain
management clinic, is there a statistically significant difference in the proportions of White and
Hispanic patients that engage in aberrant drug-related behaviors?
While the actual study conducted in this dissertation did not answer our original question,
it did evaluate the incidence of ADRB in the two cohorts with the greatest number of patient
records: White and Hispanic. These two groups account for most of the patients at the pain clinic,
which makes them relevant to the analysis. The results showed that there is no statistically
significant difference in the proportion of incident ADRB between White and Hispanic patients.
As in the analysis of OMS, this was true for both the first (baseline) and subsequent visits.
However, only the first visit had enough patient records for a sample size suitable for inferential
statistics (n = 172). ADRB (baseline) incidence rates between cohorts were (White = 36.2% vs.
Hispanic = 33.0%), which are statistically identical (p = 0.663).
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3. Among non-malignant chronic pain patients on COT from an El Paso, Texas pain
management clinic, is there a statistically significant difference in the proportions of men and
women that engage in aberrant drug-related behaviors?
There was no statistically significant difference in the proportions of incident ADRB
(baseline) between males and females (p = 0.314). ADRB incidence rates for first visit were as
follows: (Male = 37.8% vs. Female = 30.8%). Out of the three risk variables, Sex was the one
that got closer to attaining statistical significance. ADRB rates were most discrepant between
Males and Females than between any of the other cohort pairs. Although this discrepancy can be
merely due to chance (failed to reject the H0), it may warrant further inquiry in future studies.
Overall, none of the risk variables tested showed statistically significant associations to
incident ADRB, the outcome variable. The implication of these results is that the data clearly
showed (very small χ2 statistic numbers) that we should not expect for a patient with variant
metabolism of CYP2D6 substrates to be more predisposed to abuse or misuse of medication
and/or illicit drugs, or at least, not at a higher rate than what we would expect to see in a patient
with normal CYP2D6 metabolism. The same was true (no statistically significant incident
discrepancies) for White patients versus Hispanic patients and Males versus Females. Although
with the later comparison and based on incidence statistics alone, one might be forgiven for
being inclined to believe that Males were more likely than Females to engage in ADRB.
However, as pointed before, the difference could have been the result of chance alone. It is
important to note that the conclusions reached here are the result of statistical analyses conducted
on the first (baseline) visit sample only. Of the two samples collected, only the first visit sample
had the size and sampling ratio (κ) that allowed for the detection of smaller differences in
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proportions (small ES) while keeping α = 0.05 (minimizing type I error) and 1-β = 0.80
(minimizing type II error).
The initial data collection protocol called for at least a second set of data to be retrieved on
the same patient for a subsequent office visit. There were a couple of reasons for this. First, we
needed to ensure there would be something to detect (i.e. a positive consistent opioid result,
negative inconsistent opioid result) as it was initially assumed that most patients would not be
taking any opioid medication on their first visit to the clinic. This would have been the case (per
pain clinic policy) if not for the fact that the first visit was assumed to be the one when the PGT
collection took place. This meant that most patients (>80%) were already taking at least one opioid
by the time they came to that office visit. This also meant that, contrary to what was initially
thought, a complete assessment of aberrant drug related behaviors was in fact possible and
appropriate at this time. The second reason was to assess the potential for confounding from
repeated drug testing events (decrease in positivity rates) (A. J. Pesce et al., 2011). This required
inter-visit time periods to be approximately equal between cohorts. However, as detailed in
methods, significant variability in inter-visit times (7 days to 3+ years) made this impossible to
achieve. Furthermore, second visit data was not used on any of the analyses due to the large amount
of missing paired UDT data values (n = 69).
5.1 Implications of Study Results
An important implication of what was found is that the data did not support the main
hypothesis. This means that it could not have been used for the creation of biometric tool for risk
assessment as initially conceived, nor that data from the study could have been feed into automated
decision support systems. This also means that the risk assessment process will for now continue
to rely on current methods. An interesting finding was that the data showed unexpectedly high
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total ABDR incidence rates (> 30%). While this is only true of NMCPP on COT at this clinic and
not generalizable to the public at large, it can have important implications for our approach to
curtailing these behaviors in this patient population. At the very least, it shows that we need to do
a better job at attempts to reduce ADRB in NMCPP. Finally, it is important to note that what the
data from the study really showed is that presuppositions we might have had about expecting to
see higher ADRB incidence rates for individual categories in our risk variables were in fact
incorrect. In other words, the data showed that we should not allow preconceived notions about
who we would have expected to be more likely to misuse medication or abuse an illicit substance
to dictate the quality of care a patient receives, absent any other objective assessment.
5.2 Limitations
There were some factors that limited the interpretation and generalizability of the findings
in this study. These include the following:
Although (based on the literature review) it was appropriate to assume that the main genetic
risk/exposure variable for outcome ABDR was one cytochrome P250 metabolizing enzyme only
(CYP2D6), there are in fact several other enzymes, opioid receptors (pharmacodynamic
influencers), transporter proteins and other substances implicated in pain perception that also play
a role on the biotransformation and effectiveness of the opioid drugs of interest to this study
(Codeine, Hydrocodone, Oxycodone and Tramadol). Not including these biomarkers in the
analysis could have had an effect on the interpretation of results. As a retrospective cohort study,
there is always a risk that there might have been significant confounders (other than Race and Sex)
that were not accounted for in the analysis. As an association study, there was no expectation that
a causal relationship could have been established between OMS and ADRB, had the association
been statistically significant. The dichotomization of categorical variables OMS (PM, IM, EM &
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UM transformed into NM and VM) and Race/Ethnicity (dropped Black and Asian categories due
to low representation), although necessary to achieve a sampling ratio that was closer to one (as in
the case of OMS) and to avoid bias from low representation (Race), might have masked important
individual category associations with ADRB, therefore affecting the interpretation of results. The
designation of ADRB as a binary outcome variable encompassing several statistics (UDT results,
PMP results, drug adulteration testing (DAT) results) might have oversimplified the nature of the
potential relationships between these individual statistics and the risk variables. A non-probability
convenience sample was used in this study to ensure that there were enough patient records for
each of the risk variable’s categories to meet significance and power requirements. However, the
use of this type of sampling approach might have hindered adequate representation, which reduces
generalizability. Finally, a restrictive sample inclusion criteria was used in order to minimize the
effect of additional potential confounders (a legitimate concern in retrospective cohort studies).
Beyond the issue of generalizability, the resulting reduced sample size might have had a
detrimental effect on the detection of even smaller effect sizes (ES < 10%), this was certainly true
with data collected on the second visit.
5.3 Future Directions
It is conceivable that study design choices might have partially contributed to the lack of
statistically significant associations between the study’s variables. However, the significant lack
of strength in the associations between the study’s variables (high p-values, low χ2 values) for our
sample size (n = 186, total for both cohorts) might indicate that even with larger sample sizes, and
accounting for additional confounders, there is still a good chance the same conclusion would have
been reached. Of course, this does not preclude the fact that improvements can be made to future
studies. For instance, future research could benefit from adequate sample sizes for each of the
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category levels of the dichotomized variables so that all are properly represented. Future studies
could also focus on evaluating the individual components of the outcome variable (ADRB), or on
accounting for all the genetic contribution to opioid medication effectiveness (not just CYP2D6
metabolizer status). Finally, future studies could limit the impact that an over-restrictive inclusion
criteria can have on determinations of sample size.
5.4 Conclusion
The purpose of this dissertation study was to assess the relationship between opioid
metabolism, as determined by phenotypic CYP2D6 expression, and aberrant drug-related
behaviors, such as opioid misuse, in a population of non-malignant chronic pain patients within an
El Paso, Texas pain management clinic. Significant data gathered in this study would have
informed the conception of a risk assessment tool that relied on objective biometric information.
However, the results of the study showed that there was no statistically significant association
between opioid metabolizer status and aberrant drug-related behaviors. In addition, the results also
showed that there was no statistically significant association between two suspect confounding
variables, race and gender, and aberrant drug-related behaviors. Although, no statistically
significant associations were found, a closer look at the data revealed interesting findings that merit
further exploration in studies that expand sample size and reconfigure the study’s variables for
more granular assessments.
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TITLE OF APPENDIX
Appendix A. SOAPP-R

EL PASO ORTHOPAEDIC SURGERY GROUP
SPINE CENTER OF EL PASO AND EL PASO PAIN MANAGEMENT CENTER
1755 CURIE, STE. C, EL PASO, TEXAS 79902 PHONE (915) 533-7465 · FAX (915) 534-1246
www.eposg.com

SOAPP®-R
The following are some questions given to patients who are on or being considered for
medication for their pain. Please answer each question as honestly as possible. There are no
right or wrong answers.

0

1

2

3

4

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

6. How often have you counted pain pills to see
how many are remaining?

○

○

○

○

○

7. How often have you been concerned that people
will judge you for taking pain medication?

○

○

○

○

○

○

○

○

○

○

1. How often do you have mood swings?
2. How often have you felt a need for higher doses
of medication to treat your pain?
3. How often have you felt impatient with your
doctors?
4. How often have you felt that things are just too
overwhelming that you can't handle them?
5. How often is there tension in the home?

8. How often do you feel bored?
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9. How often have you taken more pain medication
than you were supposed to?

○

○

○

○

○

10. How often have you worried about being left
alone?

○

○

○

○

○

11. How often have you felt a craving for
medication?

○

○

○

○

○

○

○

○

○

○

12. How often have others expressed concern over
your use of medication?

©2009 Inflexxion, Inc. Permission granted solely for use in published format by individual practitioners
in clinical practice. No other uses or alterations are authorized or permitted by copyright holder.
Permissions questions: PainEDU@inflexxion.com. The SOAPP®-R was developed with a grant from
the National Institutes of Health and an educational grant from Endo Pharmaceuticals.

EL PASO ORTHOPAEDIC SURGERY GROUP
SPINE CENTER OF EL PASO AND EL PASO PAIN MANAGEMENT CENTER
1755 CURIE, STE. C, EL PASO, TEXAS 79902 PHONE (915) 533-7465 · FAX (915) 534-1246
www.eposg.com

0

1

2

3

4

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

16. How often have you run out of pain medication
early?

○

○

○

○

○

17. How often have others kept you from getting
what you deserve?

○

○

○

○

○

13. How often have any of your close friends had a
problem with alcohol or drugs?
14. How often have others told you that you had a
bad temper?
15. How often have you felt consumed by the need
to get pain medication?
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18. How often, in your lifetime, have you had legal
problems or been arrested?

○

○

○

○

○

19. How often have you attended an AA or NA
meeting?

○

○

○

○

○

20. How often have you been in an argument that
was so out of control that someone got hurt?

○

○

○

○

○

○

○

○

○

○

22. How often have others suggested that you have
a drug or alcohol problem?

○

○

○

○

○

23. How often have you had to borrow pain
medications from your family or friends?

○

○

○

○

○

24. How often have you been treated for an alcohol
or drug problem?

○

○

○

○

○

21. How often have you been sexually abused?

Please include any additional information you wish about the above answers. Thank you.
©2009 Inflexxion, Inc. Permission granted solely for use in published format by individual practitioners
in clinical practice. No other uses or alterations are authorized or permitted by copyright holder.
Permissions questions: PainEDU@inflexxion.com. The SOAPP®-R was developed with a grant from
the National Institutes of Health and an educational grant from Endo Pharmaceuticals.
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Appendix B. COMM
COMM™
Please answer each question as honestly as possible. Keep in mind that we are only asking about
the past 30 days. There are no right or wrong answers. If you are unsure about how to answer
the question, please give the best answer you can.

Please answer the questions using
the following scale:
0

1

2

3

4

1. In the past 30 days, how often have you
had trouble with thinking clearly or had
memory problems?

O

O

O

O

O

2. In the past 30 days, how often do
people complain that you are not
completing necessary tasks? (i.e., doing
things that need to be done, such as
going to class, work or appointments)

O

O

O

O

O

3. In the past 30 days, how often have you
had to go to someone other than your
prescribing physician to get sufficient
pain relief from medications? (i.e.,
another doctor, the Emergency Room,
friends, street sources)

O

O

O

O

O

O

O

O

O

O

O

O

O

O

O

O

O

O

O

O

4. In the past 30 days, how often have
you taken your medications
differently from how they are
prescribed?
5. In the past 30 days, how often have
you seriously thought about hurting
yourself?
6. In the past 30 days, how much of your
time was spent thinking about opioid
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medications (having enough, taking
them, dosing schedule, etc.)?

Please answer the questions using
the following scale:
0

1

2

3

4

7. In the past 30 days, how often have you
been in an argument?

O

O

O

O

O

8. In the past 30 days, how often have
you had trouble controlling your anger
(e.g., road rage, screaming, etc.)?

O

O

O

O

O

9. In the past 30 days, how often have you
needed to take pain medications
belonging to someone else?

O

O

O

O

O

10. In the past 30 days, how often have
you been worried about how you’re
handling your medications?

O

O

O

O

O

11. In the past 30 days, how often have
others been worried about how you’re
handling your medications?

O

O

O

O

O

O

O

O

O

O

13. In the past 30 days, how often have
you gotten angry with people?

O

O

O

O

O

14. In the past 30 days, how often have
you had to take more of your
medication than prescribed?

O

O

O

O

O

15. In the past 30 days, how often have
you borrowed pain medication from
someone else?

O

O

O

O

O

12. In the past 30 days, how often have
you had to make an emergency phone call
or show up at the clinic without an
appointment?
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16. In the past 30 days, how often have
you used your pain medicine for
symptoms other than for pain (e.g., to
help you sleep, improve your mood, or
relieve stress)?

O

O

O

O

O

0

1

2

3

4

O

O

O

O

O

Please answer the questions using
the following scale:
17. In the past 30 days, how often have
you had to visit the Emergency Room?
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Appendix C. IRB Exemption Request

Institutional Review Board Office
The University of Texas at El Paso
Office of Research and Sponsored Projects

Exemption Request Application
Instructions: This form must be reviewed and completed in its entirety. This form is to be submitted to the
IRB only when an investigator is contemplating the initiation of a research or capstone project, which,
in the investigator’s judgment, may be exempt from full IRB review. Please type and submit this form
along with finalized copies of all project related materials via IRBNet. Study information sheets can be
used in lieu of consent forms for exempt research projects. See forms section for more information.
Attention to these elements will facilitate the IRB’s review of your project. The IRB will then determine
whether the activity is covered by the allowable Exempt regulations. Research activities are exempt
from regulations for the protection of human research subjects when they are considered minimal risk
( the probability or magnitude of harm or discomfort anticipated in the research are not greater in and
of themselves than those ordinarily encountered in daily life or during the performance of routine
physical or psychological examinations or tests (as defined by 45 CFR 46.101), and the ONLY
involvement of human subjects falls within one or more of the exempt categories.

The Federal Office for Human Research Protections (OHRP) has allowed for six exempt categories.
The exempt categories outlined below are based solely on methods of research, and do not take the level
of risk into consideration. Although most exempt research requires no further oversight to be
conducted ethically, some exempt research raises ethical concerns or requires measure to protect
participants. As such, the IRB will not consider any research exempt that does not fulfill ethical
principles reflected in the Belmont Report. These three basic ethical principles are:
Respect for Persons (autonomy)- individuals should be treated as autonomous agents and persons with
diminished autonomy are entitled to protection.
Beneficence- human participants should not be harmed and the research should maximize possible
benefits and minimize possible harms.
Justice- the benefits and risks of research must be fairly distributed.
Research that otherwise would be exempt by federal regulations that raises ethical concerns or requires
measures to protect participants may be denied and/or moved to a higher level of review.
For further guidance or assistance, please contact the IRB office at (915) 747-7693 or by email at
irb.orsp@utep.edu.
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Project Information
Project Title

ASSOCIATION OF OPIOID METABOLISM WITH ABERRANT DRUG-RELATED
BEHAVIORS AMONG NON-MALIGNANT CHRONIC PAIN PATIENTS

Principal Investigator
(Last Name, First
Name)

Eduardo Aguila

University Title

☐ Faculty/Staff

Department

Interdisciplinary Health Sciences

 Student

Co-Investigator
(Last Name, First
Name)
University Title
Protocol Title:
E-mail Address

Human Subjects
Research Training
Completed:

☐ Faculty/Staff

☐ Student

ASSOCIATION OF OPIOID METABOLISM WITH ABERRANT DRUG-RELATED
BEHAVIORS AMONG NON-MALIGNANT CHRONIC PAIN PATIENTS
Phone Number
lalord78@gmail.com
(915) 490-6530
Summer
semester of
2018 upon IRB
approval with
retrieval of data
from Jan 2016
Anticipated Start
through March
Date
2018
 Yes
☐ No
Anticipated End
(retrospective
Date:
collection of
existing data.
Initially
generated as
part of standard
of care)

If the Principal Investigator is a student, the faculty advisor must indicate knowledge and approval of this
submission. By electronically signing the package in IRBNet, the faculty advisor certifies that the study is
under their direct supervision and that the faculty advisor is responsible for ensuring that all provisions of
the IRB approval are complied with by the investigator.
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A. Type of Project
Check all that apply

☐ Faculty Research

☐ Thesis



☐ Presentation/Conference

☐ Capstone

☐

☐ Funded-Source:

☐ Publication:

☐

Dissertation
Internal Evaluation/NonPublishing
Other:

B. Applicability
C1. Does the study protocol include children as research subjects?
(see 45 CFR 46.101(b)(2))
C2. Does the study protocol include prisoners, fetuses, pregnant women, or human in vitro fertilization?

YES ☐ NO  N/A ☐

C3. Does the protocol involve more than minimal risk?

YES ☐ NO 

C4. Does the protocol involve deception?

YES ☐ NO 

C5. Does the protocol include cognitively impaired participants as research subjects?

YES ☐ NO 

YES ☐ NO  N/A ☐

If you answered yes to any of the above, the submission does not qualify for exemption. Please fill out a full study
protocol.

C. Exempt Research Categories
Check the applicable category below. Only answer questions related to the applicable category.

☐ Category 1

EDUCATIONAL

a.

Will the researchers use their current students or trainees as participants?
YES ☐ NO ☐
Please explain what additional measures will be taken to ensure participants do not
feel pressured or coerced during recruitment for or participation in the research:

☐ Category 2

SURVEYS, INTERVIEWS, EDUCATIONAL TESTS, AND OBSERVATION OF PUBLIC BEHAVIOR

a.
b.

c.

Will the researchers use their current students or trainees as participants?
YES ☐ NO ☐
Will the research involve children in survey procedures, interview procedures, or
observation of public behavior when the investigator(s) participate in the activities
being observed?
YES ☐ NO ☐
If yes, this study does not meet the criteria for exemption.
Will you record information in a way that human subjects can be identified, directly
or through identifiers (coded) linked to the subjects?
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d.

YES ☐ NO ☐
Could any disclosure of the subjects’ responses outside the research reasonably
place the subjects at risk of criminal or civil liability or be damaging to the subjects’
financial standing, employability, insurability, or reputation?
YES ☐ NO ☐

☐ Category 3

ELECTED OR APPOINTED PUBLIC OFFICIALS OR CANDIDATES FOR PUBLIC OFFICE

 Category 4

EXISTING DATA

a.

What is the source of the data?
☐ Publicly available database
Include Link:
 Medical or Private Records

☐ Student Records
CIERP will be providing dataset: YES ☐ NO ☐
☐ Another PI/Researcher collected it in the

past
Do you have permission to use this data? NO ☐ YES 
If yes, describe how and attach documentation indicating permission.
Granted by the covered entity’s chief medical officer after a review of the study’s
protocol.
b.
c.

Will this data be stripped of any identifiers?
YES  NO ☐
Will you be using a data collection form? Attach documentation and/or list data
points.
YES ☐ NO 

Please note that HIPAA prohibits the collection of specified identifiers such as name, street address,
telephone/fax numbers, e-mail address, URLs & IP addresses, social security numbers, certificate/license
number, vehicle/serial identifiers and full face photos.
☐ Category 5

ONLY USED BY OR WITH THE APPROVAL OF GOVERNMENT AGENCIES

☐ Category 6

TASTE/FOOD QUALITY EVALUATION & CONSUMER ACCEPTANCE
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D. Project Site(s): Check all that apply
This includes subject recruitment, subject enrollment, data collection, and data analysis

☐ Project will be conducted entirely at UTEP.
☐ Research will be conducted at another institution.*
Project will be reviewed by another IRB and/or Ethics Committee
Provide the institution name and contact person:
 Other*: Study to be conducted at the El Paso Orthopaedic Surgery Group Toxicology Laboratory.
Approved by Medical Director/Medical Chief of Staff (Authorization attestation attached).
*Please include applicable Authorization Letter(s) indicating permission to conduct project in the submission package

E. Ethical Considerations:
E1. Does this project include inclusion and exclusion criteria?
IF yes, please describe:

The records to be used in the study will originate from a subset of the chronic pain patient
population who meet the following inclusion criteria:
•

non-malignant chronic pain patients (NMCPP) on chronic opioid therapy (COT) who visit
our pain clinic;

•

male or female, of any race/ethnicity who are at least 18 years of age, and;

•

had been diagnosed with any kind of chronic pain of non-cancerous origin,

•

had been prescribed COT with one or several substrates of the CYP2D6 metabolizing

YES  NO ☐ N/A ☐

enzyme,
•

had signed an opioid treatment agreement,

•

have had Texas Prescription Drug Monitoring Program (PMP) data retrieved recently,

•

have had risk assessment/stratification performed with The Screener and Opioid Assessment
for Patients with Pain-Revised (SOAPP-R) and/or The Current Opioid Misuse Measure
(COMM) instruments, and;

•

have had urine drug testing/pharmacogenetic testing performed in association with the COT
regimen.

E2. Will you be audio or video recording during any portion of this project?
IF yes, please describe:
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YES ☐ NO  N/A ☐

E3. Does the project pose any risk to the individual(s)?
IF yes, please describe how the risk/benefit ratio has been weighed and explain how you will address this
concern:

YES ☐ NO 

E4. Will subjects benefit from participating in the research? (compensation is not a benefit)
Describe and assess potential benefits to be gained by participants (if any) and the benefits that may accrue to
society in general:

The aim of the proposed study is to describe whether a statistically significant association
exists between opioid metabolism and aberrant drug-related behaviors among non-malignant chronic pain
patients. If such an association is proven to be significant, it would become the theoretical underpinnings
of a new tool for COT aberrant drug-related behaviors (ADRB) risk assessment, which would be guided
by objective biometric data rather than more subjective information, as in the case of the tools that are

YES  NO ☐ N/A ☐

currently available (i.e. SOAPP-R and COMM). This new tool could be of substantial clinical value to
pain management practitioners since it would enable them to make use of genotypic data to better predict
which patients are at a greater risk of engaging in aberrant drug-related behaviors. Moreover, the data
generated could be feed into algorithms for protocol creation, and be incorporated into a laboratory’s
information system (LIS) decision support modules. Finally, the insight gathered by the tool would
streamline patient risk stratification, which in turn would enable better care.
E4. Is there a possibility of coercion or undue influence?
IF yes, please describe how you will address this concern:

YES ☐ NO 

E5. Will subjects be compensated (payment, incentives, extra credit, etc.)?
IF yes, please describe:

YES ☐ NO  N/A ☐

E6. Will this project use social media, internet websites, or any other web based software?
IF yes, please describe and include link(s):

YES ☐ NO 

E7. Will identifiable data be made available to anyone other than the Principal Investigator and approved study
staff?
IF yes, explain who and why they will have access to the identifiable data:

YES ☐ NO  N/A ☐

E7. Will the results of the project be disseminated? Check all that apply.

Results are to become part of a dissertation study, which will be both, published and orally presented.
 Publication

 Presentation

F. Literature Review:
In this section describe the significance of the proposed project. Provide appropriate references.
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YES  NO ☐ N/A ☐

An estimated 100 million Americans suffer from some form of chronic pain (Cone, Caplan, Black,
Robert, & Moser, 2008; Institute of Medicine, 2011; Webster, 2010). Chronic opioid therapy (COT) use
in non-malignant chronic pain patients (NMCPP) has markedly increased over the past two decades due
to growing consensus that COT is suitable for the treatment of moderate-to-severe non-malignant chronic
pain (Chou et al., 2009). Yet, COT for NMCPP has been widely associated with multiple aberrant drugrelated behaviors (ADRB) such as misuse, abuse, diversion, addiction, and pseudoaddiction (Webster,
2010). One reason for the relative high incidence of ADRB among NMCPP on COT may be geneticsinduced medication response variability, which, can result in pharmacotherapy failure and/or toxicity
The present study will aim at uncovering potential relationships between opioid metabolizer
status (OMS) (caused by inter-personal genetic variability in opioid metabolism) and ADRB such as
illicit substance abuse and prescription opioid misuse. Pharmacogenetic testing (PGT) will be used to
categorize patient OMS, whereas urine drug testing (UDT) will identify relevant ADRB. The findings of
the study could contribute to the creation of better prediction algorithms that make use of genetic
biomarkers for reducing the likelihood of at-risk NMCPP on COT, those who may be variant opioid drug
metabolizers, of engaging in ADRB.
To test the study’s hypothesis, unidentified retrospective categorical data from an assembled
cohort of NMCPP on COT retrieved from a Pain Management Clinic’s electronic medical records system
(EMR) – PGT and UDT results – will be cross-tabulated and analyzed with the Pearson Chi-square test
for difference in proportions and test of independence. However, the Fisher’s Exact test or Likelihood
Ratio Chi-Square will be used if expected cell count is low. Confounding and effect modification will be
dealt with by the inclusion of suspect variables in a logistic regression model and, if necessary, by
reporting findings separately for different variable levels.
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G. Summary of Project Activity:
Briefly state the purpose of this research project and your research question(s):
The purpose of this study is to assess the relationship between opioid metabolism and aberrant drugrelated behaviors among non-malignant chronic pain patients. Significant findings could further advance the
creation of better ADRB prediction algorithms for at-risk patients on a chronic opioid regimen.
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The main questions of the study are the following:
2) Among non-malignant chronic pain patients from an El Paso, Texas pain management clinic, are opioid
metabolizer status and aberrant drug-related behaviors independent?
3. Among non-malignant chronic pain patients from an El Paso, Texas pain management clinic, are
race/ethnicity of patients on chronic opioid therapy and aberrant drug-related behaviors independent?
4. Among non-malignant chronic pain patients from an El Paso, Texas pain management clinic, is there
a statistically significant difference in the proportion of men and women on chronic opioid therapy that engage
in aberrant drug-related behaviors?
What is the project goal(s)? Please include the specific population geared to benefit from this project:
The main goal of this project is to uncover statistically significant associations between opioid metabolism
and aberrant drug related behaviors to advance the creation of better and more accurate ABDR prediction
tools for at-risk non-malignant chronic pain patients on chronic opioid regimens.
Describe the informed consent process plan. How will participants be fully informed of this research prior to
their participation and how will their voluntary consent be documented. * Note: Please SUBMIT a copy of the
form(s).
No informed consent process plan is required as the study will only make use of properly de-identified
existing data initially collected as standard of care.
Describe how the project will be implemented. Describe the task(s) subjects will be asked to perform. List what
procedures you will follow and what the study participants will be exposed to. Please provide details (# of
subjects, procedures, duration, etc.). Alternately, describe the study plan for a project working with existing
data (# of files, specimens, time frame, etc.)
The Principal Investigator (PI) and his professional assistant (all will undergo CITI training for the
protection of human participants and certificates are to be forwarded to the IRB office) will retrieve
approximately 100-110 individual drug testing patient records for each cohort (n = 200-220) from either the
clinic’s own EMR: Prime Suite (Greenway Health, 2017), the clinic’s toxicology laboratory cloud-based
information system (LIS): AxisLabsDX (Alternative Biomedical Solutions, 2017), and/or Alere Toxicology

96

web portal: Alere Datalink (Alere, 2017). Only pertinent variable data (opioid, illicit substance and
adulterant results) along a non-PHI unifying identifier will be extracted on to an excel database.
The same procedure will be applied to the retrieval of genetic testing, gender and race/ethnicity data.
However, in addition to the sources mentioned above, data will also be retrieved from the Millennium
Health, AltheaDx, AssureX, Vantari Genetics, PinPoint Molecular and Proove Biosciences web portals
(AltheaDx, 2017; AssureX Health, 2017; Millennium Health, 2017; PinPoint Molecular, 2017; Proove
Biosciences, 2017; Vantari Genetics, 2017). Pertinent variable data will be extracted along the
aforementioned unifying identifier (i.e. Study ID #).
Anticipated collection of this existing record data (initially collected as standard of care from January 2016
through March of 2018) will take place in the summer of 2018 upon obtaining explicit IRB approval. The PI
will then be responsible for analyzing the collected data.
Describe how the project team will protect the privacy of study participants:
There are no study participants in this project.
Could the information obtained or recorded about subjects place them at risk of criminal or civil liability or be
damaging to the participants’ financial standing, employability, insurability, or reputation?
YES ☐ NO  N/A ☐
If yes, please explain:
Describe how the project team will collect, manage, and analyze data.
Describe provisions that will be taken to maintain confidentiality of the data. Will it contain subject names or
images? (e.g surveys, video, audio tapes, database) The PI will be responsible for manipulating the data
extracted on to the excel database. Patient data from various sources will be consolidated for each patient
record with the aid of a unifying identifier. To ensure confidentiality, no protected health information (PHI)
identifying individual patients (i.e. name, date of birth) is to be retrieved and added to the study’s database
spreadsheet. After subsequent cleaning of data, secondary variables will be created to properly address the
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study’s research questions. Secondary data variables used in the study’s analyses will also be devoid of any
PHI.
Describe the security plan for data, including where data will be stored, and for how long, noting that you may
not keep identifiable data indefinitely (i.e., password protection, encrypted, locked filing cabinet, etc.):
Safeguarding patient information (even if not PHI) and ensuring confidentiality is of paramount importance.
All patient record data will be further manually deidentified (by elimination/transformation of any non-PHI
variables or variable relationships that in conjunction could be traced back to an individual), and statistically
de-identified (by presenting aggregate data and summary statistics only). Only the PI and his professional
assistant at the EL Paso Orthopaedic Surgery Group’s (EPOSG) Toxicology Laboratory will have access to
the patient data. Data manipulation and statistical analyses will only be performed on the PI's passwordprotected device. The study's data will be stored in the PI's password-protected device and at one of the
password-protected devices of the aforementioned facility where access is highly restricted.

ASSURANCES – Conflict of Interest and Fiscal Responsibility
All UTEP researchers (faculty, staff, and students) and outside collaborators who will be conducting human subjects’ research
(intervention and/or interaction) must complete human subject research ethics training in order to conduct research with human
participants.

Do you or any person responsible for the design, conduct, or reporting of this project have an economic
interest in, or act as an officer or director of any outside entity whose financial interests may reasonably
appear to be affected by this project?
If yes, please explain any potential conflict of interest
Do you or any person responsible for this project have existing financial holdings or relationships with
the sponsor of this study?
If yes, please explain any potential conflict of interest

YES ☐ NO


YES ☐ NO
 N/A ☐

Principal Investigator Certifications:
With this submission I certify that:
 I agree to fully comply with the ethical principles and regulation regarding the protection of human subjects
in research.
 I agree that the information provided in this form and all other supporting documents are accurate and
complete.
 I accept responsibility for making sure all study personnel involved in the project have been appropriately
trained. PI affirms responsibility for keeping training records on file for all study personnel.
 I understand that any changes in procedure with affect to participants must be submitted to the IRB for written
approval prior to their implementation. Furthermore, I understand that any adverse events and significant changes
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in risk for participants must be immediately reported in writing to the UTEP IRB.
Copies of all required documentation of consent (if applicable) and any related to this research are securely stored
as outlined above.

Appendix D. Abbreviation List
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ADR – Adverse drug reactions
ADRB – Aberrant drug-related behaviors (abuse, misuse, diversion, addiction & pseudoaddiction)
AP – Absence of prescribed medication
COMM – Common opioid misuse measure
COT – Chronic Opioid Therapy
EA – Evidence of adulteration
EM – Extensive metabolizer
EMR – Electronic medical records
ES – Effect size
GC-MS – Gas chromatography mass spectrometry
IM – Intermediate metabolizer
IRB – Internal review board
LC-MS – Liquid chromatography mass spectrometry
LC-MS/MS – Liquid chromatography tandem mass spectrometry
LIS – Laboratory information system
NM – Normal metabolizer
NMCPP – Non-malignant chronic pain patients
OMS – Opioid metabolizer status (CYP2D6 enzyme)
OUD – Opioid use disorder
PDMP – Prescription drug monitoring program
PGT – Pharmacogenetic testing
PHI – Protected health information
PI – Presence of an illicit
PM – Poor metabolizer
PNP – Presence of non-prescribed medication
SOAPP-R – Screener and opioid assessment for patients with pain-revised
UDT – Urine drug testing
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UM – Ultra-rapid metabolizer
VM – Variant metabolizer
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